Piperidinyl Nociceptin Receptor Compounds

Abstract

To provide novel piperidinyl nociceptin receptor compounds.SOLUTION: The present invention provides novel piperidinyl-containing nociceptin receptor ligand compounds and pharmaceutical compositions, which are useful in the treatment of neurological diseases and conditions, where such ligands mediate the negative effects of the conditions. Such neurological diseases and conditions include acute and chronic pain, substance abuse / dependence, alcohol addiction, anxiety, depression, sleep disorders, gastrointestinal disorders, renal disorders, cardiovascular disorders and Parkinson' s disease.SELECTED DRAWING: None

Description

[Technical Field]

[0001] Statement Regarding Federally Sponsored Research This invention was made with government support under grant numbers R01DA014026, R01DA027811, R43NS070664, R43HL115984, HHSN275201300005C and HHSN275201500005C awarded by the USDapartment of Human Health and Services, National Institutes of Health. The government has certain rights in this invention.

[0002] Claiming priority under 35 U.S.C. § 119(e) This application claims priority under 35 U.S.C. §119(e) from U.S. Provisional Patent Application No. 62 / 261,871, filed December 2, 2015, which is incorporated by reference in its entirety.

[0003] Provided herein are novel compounds and pharmaceutical compositions thereof that modulate the nociceptin receptor, which may be useful in the treatment of acute and chronic pain, substance abuse / dependence, alcoholism, anxiety, depression, sleep disorders, gastrointestinal disorders, renal disorders, cardiovascular diseases, and the treatment and / or prevention of Parkinson's disease. [Background technology]

[0004] The NOP receptor, previously known as the opioid receptor-like receptor (ORL1, XOR1, and LC132), belongs to the opioid receptor family and shares nucleotide and amino acid homology with μ, δ, and κ opioid receptors. However, the NOP receptor does not bind to the opioid ligand with the high affinity expected for opioid receptors. The endogenous 17-amino acid peptide ligands for NOP, nociceptin or orphanin FQ (N / OFQ), bind with low affinity to μ, δ, and κ opioid receptors.

[0005] When administered intracerebroventricularly (icv or ICV) to mice, N / OFQ attenuates stress-induced, opioid-mediated antinociception, thereby shortening the hot plate escape jumping latency and tail flick latency in mice. Further studies have demonstrated the presence of NOP and N / OFQ precursor proteins and mRNA in the pain-processing pathway.

[0006] There is growing evidence that the N / OFQ-NOP receptor system plays an important role in reward processing and drug abuse. Moderate to high densities of NOP receptors exist in areas involved in drug reward, including the nucleus accumbens, ventral tegmental area, medial prefrontal cortex, lateral hypothalamus, amygdala, and bed nucleus of the stria terminalis. ICV administration of N / OFQ suppresses basal and drug-stimulated dopamine release in the nucleus accumbens. N / OFQ has been shown to block the rewarding properties of several common drugs of abuse. In particular, N / OFQ can block the acquisition of conditioned place preference (CPP) induced by morphine, cocaine, amphetamine, and alcohol.

[0007] The inhibitory effect of N / OFQ on morphine CPP and the inhibition of morphine-induced dopamine release in the mesolimbic region suggest that N / OFQ may function as an "anti-opioid" peptide in reward and pain (Ciccocioppo, R., et al., Peptides, 2000, 21(7):1071-1080). These studies support the involvement of NOP receptors in drug addiction and suggest the usefulness of NOP agonists as drugs for the treatment of drug abuse.

[0008] Approximately 100 million adult Americans experience some form of pain each year, a condition that costs the nation $560 billion to $635 billion annually in lost productivity and treatment ("Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research; Institute of Medicine of the National Academies, June 2011"). Opioid analgesics are the primary method of treating pain and, in many cases, the only treatment option that provides significant relief. However, opioid analgesics, which are primarily mu-opioid receptor (MOP) agonists, have the potential for abuse and are fraught with numerous life-threatening side effects, such as constipation, nausea, and tolerance, which hinder their long-term safety and effectiveness and contribute to other societal problems (pain medication overuse). Therefore, to address the great need for safe and effective pain treatments, the recently published National Pain Strategy (NINDS, Interagency Pain Research Coordinating Committee; National Pain Strategy; NIH) has been implemented. As outlined in the NINDS:2015. http: / / iprcc.nih.gov / National_Pain_Strategy / NPS_Main.htm, pain medications without the drawbacks associated with opioids are essential.

[0009] From the opioid receptor family of μ, δ (DOP), κ (KOP) and nociceptin (NOP) opioid receptors, KOP and DOP agonists have also been studied as analgesics. However, compared to NOP agonists, they do not exhibit strong analgesic properties and have poor dose separation to reduce side effects such as discomfort (in the case of KOP agonists) (Wadenberg CNS Drug Rev., 2003, 9(2):187-198) and convulsions (in the case of DOP agonists) (Negus et al., J. Pharmacol. Exp. Ther., 1994, 270(3):1025-1034; Negus et al., J. Pharmacol. Exp. Ther., 1998, 286(1):362-375). Although κ-type agonist-antagonists such as nalbuphine and butorphanol have been used clinically for several decades, they are considered to be weaker analgesics compared to MOP-based analgesics.

[0010] Meanwhile, recent developments in NOP receptor-targeting ligands have clearly emerged as potential analgesics (Lin et al., ACS Chem. Neurosci., 2013, 4(2):214-224; Linz et al., J. Pharm. Exp. Ther., 2014, 349(3):535-548; Lambert et al., Br. J. Anaesthesia, 2015, 114(3):364-366). The NOP receptor and its endogenous ligand, N / OFQ, are the fourth members of the opioid family. The NOP receptor is present in the same pain transmission pathway as other opioid receptors and generally plays an inhibitory role in neurotransmission. Due to the role of NOP receptors in pain sensation and analgesia, emerging data suggest that NOP agonists may have the potential to be superior analgesics, similar to μ-opioid agonists such as morphine, but without other drawbacks such as addiction and respiratory depression (Podlesnik et al., Psychopharmacology, 2011, 213(1):53-60; Sukhtankar et al., Res. Dev. of Opioid-Related Ligands ACS, 2013, 1131:393-416).

[0011] Studies using systemically administered non-peptide NOP agonists have demonstrated that NOP agonists have potent antinociceptive activity in several animal models of pain, particularly neuropathic and inflammatory pain (Khroyan et al., Eur. J. Pharmacol., 2009, 610(1-3):49-54; Khroyan et al., J. Pharmacol. Exp. Ther., 2011, 339(2):687-693; Sukhtankar et al., Psychopharmacology, 2014, 231(7):1377-1387). Notably, studies in non-human primates have been encouraging and consistent compared with rodent studies, showing that peptide NOP agonists such as N / OFQ and UFP-112 produce spinal antinociception when administered intrathecally in primates (Hu et al., Pain, 2010, 148(1):107-113), and that the non-peptide NOP agonist Ro64-6198 administered sc (subcutaneously) produces antinociception against capsaicin-induced allodynia and heat pain (Podlesnik, et al., Psychopharmacology, 2011, 213(1):53-60). The antinociceptive potency and efficacy of NOP agonists were comparable to those of morphine (Sukhtankar et al., Psychopharmacology, 2014, 231(7):1377-1387), but importantly, there were no pruritic, respiratory depressant, or reinforcing effects at effective doses. These findings in primates strongly support the clinical potential of NOP agonists as a novel approach to "analgesia without the opioid drawbacks" (Lin et al., ACS Chem. Neurosci., 2013, 4(2):214-224).

[0012] Studies have shown that bifunctional NOP / μ opioid agonists may also offer novel avenues for the development of non-addictive analgesics (Khroyan et al., J. Pharmacol. Exp. Ther., 2007, 320(2):934-943; Khroyan et al., J. Pharmacol. Exp. Ther., 2011, 339(2):687-693). Other studies have further confirmed that non-peptide bifunctional NOP / μ agonists may exhibit antinociceptive effects in rodent and primate pain models (Linz et al., J. Pharm. Exp. Ther., 2014, 349(3):535-548).

[0013] Parkinson's disease (PD) is clinically characterized by hypo / akinesia, rigidity, gait disturbance, and resting tremor, as well as other non-motor symptoms such as depression and cognitive decline. PD is a costly disease for both individuals and society. PD patients incur significantly more annual direct costs (e.g., medications and hospitalizations) and indirect costs (e.g., time off work, early retirement; informal home care) than healthy individuals. Therefore, in the economics of PD treatment, a therapy that prevents motor or cognitive impairment would result in a significant reduction in indirect costs with minimal increase in total medication costs. It has long been recognized that PD patients who respond stably to dopamine therapy (the current first-line treatment) gradually develop two progressive clinical events, motor fluctuations and dyskinesias (involuntary movements), which are even more disabling and for which there is only one FDA-approved therapy. The dopamine (DA) precursor levodopa (L,3,4-dihydroxyphenylalanine; L-DOPA) is the cornerstone of PD therapy and is currently often administered in combination with COMT and MAO inhibitors to prolong its bioavailability and therapeutic effect.

[0014] However, chronic L-DOPA therapy is ultimately associated with the development (within 10 years in approximately 80% of patients) of motor complications (motor fluctuations and dyskinesias), which limit its clinical efficacy and reduce patients' quality of life. Therefore, the development of drugs capable of slowing the progression of dyskinesias and / or attenuating their development in patients already experiencing movement disorders is a major unmet medical need in PD. Levodopa-induced dyskinesia (LID) is a major cause of disability and social distress in PD patients, contributing to the risk of falls and the need for caregivers, especially in advanced PD cases with other neurodegenerative pathologies (i.e., memory impairment, hallucinations, and comorbidities) (Schrag et al., Mov. Disorders, 2007, 22:938-945). Treatment options for dyskinesia are very limited, and the only commercially available anti-movement disorder treatment, the glutamate antagonist amantadine, has poor and short-lasting clinical efficacy.

[0015] The N / OFQ-NOP receptor system is widely expressed in cortical and subcortical regions of the brain, particularly in the striatum, globus pallidus, and substantia nigra (SN) neurons (regions that undergo neurodegeneration in PD). Endogenous N / OFQ has been shown to contribute to the development of PD symptoms because N / OFQ levels are elevated in the SNr after dopamine (DA) cell loss or impaired DA transmission. Such increases are also observed in the CSF of PD patients (Marti, et al., 2010). NOP receptor antagonists ameliorate parkinsonian-like symptoms in neurodegenerative (6-OHDA unilaterally lesioned rats, MPTP-treated mice, and macaques) and functional (reserpine- or haloperidol-treated) models of PD. Genetic deletion of the N / OFQ gene protects mice from the neurotoxic effects of MPTP. Mechanistic studies have revealed that the antiparkinsonian effects of NOP antagonists are achieved through normalization of the imbalance between excitatory (GLU) and inhibitory (GABA) inputs acting on the nigrothalamic neurons caused by striatal DA deafferentation. NOP antagonists also enhance the symptomatic effects of levodopa. Therefore, NOP receptor antagonists may provide symptomatic and neuroprotective effects in PD patients.

[0016] On the other hand, NOP receptor agonists have been shown to attenuate the development of abnormal involuntary movements (AIMs, rodents associated with LID) in dyskinetic rats and non-human primates exposed to L-DOPA. Thus, NOP receptor ligands have promising efficacy in animal models of Parkinson's disease.

[0017] International Publication No. WO2005 / 016913 to Ito et al. and International Publication No. WO2014 / 106238 to Spear et al. disclose compounds active at NOP receptors, which are useful as treatments for pain and CNS disorders. Piperidinyl-containing compounds active at NOP receptors are disclosed in U.S. Patent Application Publication No. 2005 / 0228023 to Zaveri et al., U.S. Patent Application Publication No. 2015 / 0315201 to Tafesse, and Mustazza et al., J.Med.Chem.2008,51:1058-1062. U.S. Patent Application Publication No. 2013 / 0225552 to Allen et al. disclose heterobicyclic compounds that are PDE10 inhibitors. However, there is still a need for novel NOP receptor ligands. Summary of the Invention [Problem to be solved by the invention]

[0018] The present invention fulfills this and other needs by providing novel piperidinyl nociceptin receptor compounds that may be useful in the treatment and prevention of a variety of disease states. [Means for solving the problem]

[0019] In one embodiment, a compound of structural formula (I): [ka] (Wherein A is [ka] and B is hydrogen; or alternatively, A and B are absent and the carbon atoms to which they are attached are [ka] is the carbon atom adjacent to the amide carbonyl atom of; R and R together with the carbon atoms to which they are attached form an aryl, substituted aryl, heteroaryl, or substituted heteroaryl; X is hydrogen, -C=NOR, -C(O)NR, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, or substituted heteroarylalkyl; Y is hydrogen, -C=NOR, -C(O)NR, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, or substituted heteroarylalkyl; T is =NR 10 ;=CR 11 R 12 -, -NR 13 R 14 R3 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, or substituted heteroarylalkyl; provided that R1 and R2 form a phenyl ring and L is [ka] where R3 is not hydrogen or methyl; R4 is hydrogen, alkyl, or substituted alkyl; R5 is hydrogen, alkyl, or substituted alkyl; and R6 is hydrogen, alkyl, substituted alkyl, or OR. 15 R7 is hydrogen, alkyl, or substituted alkyl; R8 and R9 are independently hydrogen, alkyl, or substituted alkyl; R 10 is hydrogen, alkyl, substituted alkyl, -OR 16 or -NR 17 R 18and;R 11 is hydrogen, alkyl, substituted alkyl, -C(O)R 19 or -CN; R 12 is hydrogen, -C(O)R 20 or -CN; R 13 is hydrogen or -C(O)R 21 and;R 14 is hydrogen or -C(O)R 22 However, R 13 and R 14 and R are not both hydrogen; 15 is hydrogen, alkyl or substituted alkyl, and R 16 is hydrogen, alkyl or substituted alkyl; R 17 is hydrogen or -C(O)R 23 and;R 18 is hydrogen or -C(O)R 24 and;R 19 and R 20 independently -NR 25 R 26 , -OR 27 , alkyl, substituted alkyl, heteroalkyl, or substituted heteroalkyl; R 21 and R 22 independently -NR 28 R 29 , -OR 30 , alkyl, substituted alkyl, heteroalkyl, or substituted heteroalkyl; R 23 and R 24 are independently alkyl or substituted alkyl; R 25 , R 26 , R 27 , R 28 , R 29 and R 30 are independently hydrogen, alkyl, or substituted alkyl; L is (C3-C8)cycloalkyl, (C3-C8)substituted cycloalkyl, (C3-C8)cycloheteroalkyl, (C3-C8)substituted cycloheteroalkyl, [ka] or a salt, hydrate or solvate thereof.

[0020] Derivatives of the compounds described herein, including salts, esters, enol ethers, enol esters, solvates, hydrates, metabolites, and prodrugs, are also provided. Additionally, compositions comprising the compounds provided herein and solvents are provided.

[0021] Also provided herein are methods for treating, preventing, or ameliorating symptoms of medical disorders, such as Parkinson's disease, cardiovascular disease, gastrointestinal disease, alcoholism, acute and chronic pain, anxiety, depression, pain, sleep disorders, and substance abuse / dependence. In practicing the method, a therapeutically effective amount of a compound or a pharmaceutical composition thereof is administered to a subject.

[0022] Also provided herein are methods for modulating nociceptin receptors using the compounds and compositions described herein. In practicing the methods, a therapeutically effective amount of the compound or pharmaceutical composition is administered. DETAILED DESCRIPTION OF THE INVENTION

[0023] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In the event that there are multiple definitions for a term herein, those in this section prevail unless stated otherwise.

[0024] "Alkyl," by itself or as part of another substituent, refers to a saturated or unsaturated, branched, straight, or cyclic monovalent hydrocarbon radical derived by removing one hydrogen atom from one carbon atom of a parent alkane, alkene, or alkyne. Typical alkyl groups include, but are not limited to, methyl; ethyl, such as ethanyl, ethenyl, and ethynyl; propan-1-yl, propan-2-yl, cyclopropan-1-yl, prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), and cycloprop-1-en-1-yl; propyl, such as cycloprop-2-en-1-yl, prop-1-yn-1-yl, and prop-2-yn-1-yl; butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, and 2-methyl-propan-1-yl. butyl, such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobut-1,3-dien-1-yl, but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl; and the like. The term "alkyl" is specifically intended to include groups having any degree or level of saturation, i.e., groups having only single carbon-carbon bonds, groups having one or more double carbon-carbon bonds, groups having one or more triple carbon-carbon bonds, and groups having a mixture of single, double, and triple carbon-carbon bonds. Where a specific level of saturation is intended, the expressions "alkanyl," "alkenyl," and "alkynyl" are used. In some embodiments, an alkyl group contains 1 to 20 carbon atoms (C1-C 20 In another embodiment, the alkyl group contains 1 to 10 carbon atoms (C1 to C 10In yet another embodiment, an alkyl group contains 1 to 6 carbon atoms (C1-C6 alkyl). The term "cyclic monovalent hydrocarbon group" also includes single radicals and polycyclic hydrocarbon ring systems having 3 to 12 carbon atoms. Exemplary polycyclic cycloalkyl rings include, for example, norbornyl, pinyl, and adamantyl.

[0025] "Alkanyl," by itself or as part of another substituent, refers to a saturated branched, straight-chain, or cyclic alkyl group derived by removing one hydrogen atom from one carbon atom of a parent alkane. Typical alkanyl groups include, but are not limited to, methanyl; ethanyl; propanyl, such as propan-1-yl, propan-2-yl (isopropyl), cyclopropan-1-yl; butanyl, such as butan-1-yl, butan-2-yl (sec-butyl), 2-methyl-propan-1-yl (isobutyl), 2-methyl-propan-2-yl (t-butyl), cyclobutan-1-yl; and the like.

[0026] "Alkenyl," by itself or as part of another substituent, refers to an unsaturated branched, straight-chain, or cyclic alkyl group having at least one carbon-carbon double bond derived by the removal of a hydrogen atom from a single carbon atom of a parent alkene. The group can be in either the cis or trans configuration about the double bond. Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl, cycloprop-1-en-1-yl; cycloprop-2-en-1-yl; butenyls such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl; and the like.

[0027] "Alkynyl," by itself or as part of another substituent, refers to an unsaturated branched, straight-chain, or cyclic alkyl group having at least one carbon-carbon triple bond derived by removing a hydrogen atom from a carbon atom of a parent alkyne. Typical alkynyl groups include, but are not limited to, ethynyl; propynyls such as prop-1-yn-1-yl and prop-2-yn-1-yl; butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, and but-3-yn-1-yl; and the like.

[0028] "Aryl," by itself or as part of another substituent, refers to a monovalent aromatic hydrocarbon group, as defined herein, derived by removing one hydrogen atom from one carbon atom of a parent aromatic ring system. Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalenene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the like. In some embodiments, an aryl group contains 6 to 20 carbon atoms (C6-C8). 20 In another embodiment, the aryl group contains 6 to 15 carbon atoms (C 15 In yet another embodiment, the aryl group contains 6 to 15 carbon atoms (C 10 aryl).

[0029] "Arylalkyl," by itself or as part of another substituent, refers to an alkyl group having a carbon atom, typically a terminal or sp 3It refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom is replaced with an aryl group, as defined herein. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethene-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl, and the like. Where specific alkyl moieties are intended, the nomenclature arylalkanyl, arylalkenyl, and / or arylalkynyl is used. In some embodiments, arylalkyl groups are those having a carbon atom (C6-C8). 30 ) arylalkyl, for example, the alkanyl, alkenyl, or alkynyl portion of the arylalkyl group is (C1-C 10 ) alkyl, and the aryl portion is (C6-C 20 In another embodiment, the arylalkyl group is (C6-C 20 )arylalkyl, for example, the alkanyl, alkenyl, or alkynyl portion of the arylalkyl group is (C1-C8)alkyl and the aryl portion is (C6-C 12 In yet another embodiment, the arylalkyl group is (C6-C 15 )arylalkyl, e.g., the alkanyl, alkenyl, or alkynyl portion of the arylalkyl group is (C1-C5)alkyl and the aryl portion is (C6-C 10 ) aryl.

[0030] "Compound" refers to a compound encompassed by the structural formulae disclosed herein, including any specific compound whose structure falls within the formulae disclosed herein. A compound may be identified by either its chemical structure and / or chemical name. In the event of a conflict between the chemical structure and / or chemical name, the identity of the compound is determined by the chemical structure. The compounds described herein may contain one or more chiral centers and / or double bonds and therefore may exist as stereoisomers, such as double bond isomers (i.e., geometric isomers), enantiomers, or diastereomers. Thus, the chemical structures depicted herein encompass all possible enantiomers and stereoisomers of the depicted compounds, including stereoisomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric and stereoisomeric mixtures. Enantiomeric and stereoisomeric mixtures can be separated into their component enantiomers or stereoisomers using separation or chiral synthesis techniques well known to those skilled in the art. Compounds can also exist in several tautomeric forms, including the enol form, the keto form, and mixtures thereof. Thus, the chemical structures depicted herein encompass all possible tautomeric forms of the depicted compounds. The compounds depicted also include isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass normally found in nature. Examples of isotopes that may be incorporated into compounds of the invention include, but are not limited to, 2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 17 O and the like. Compounds can exist in unsolvated or non-hydrated forms, as well as solvated forms, including hydrated forms, and as N-oxides. In general, compounds may be hydrates, solvates, or N-oxides. A given compound may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated herein and are intended to be within the scope of the present invention. Furthermore, when a substructure of a compound is shown, it should be understood that parentheses indicate the point of attachment of this substructure to the rest of the molecule.

[0031] "Halo," by itself or as part of another substituent, refers to a -F, -Cl, -Br, or -I group.

[0032] "Heteroalkyl," "heteroalkanyl," "heteroalkenyl," and "heteroalkynyl," by themselves or as part of another substituent, refer to alkyl, alkanyl, alkenyl, and alkynyl groups, respectively, in which one or more of the carbon atoms (and optionally any associated hydrogen atoms) have each been replaced, independently of one another, with the same or different heteroatoms or heteroatomic groups. Exemplary heteroatoms or heteroatomic groups that may replace carbon atoms include, but are not limited to, -O-, -S-, -N-, -Si-, -NH-, -S(O)-, -S(O)2-, -S(O)NH-, -S(O)2NH-, and the like, and combinations thereof. The heteroatom or heteroatomic group may be located at any interior position of the alkyl, alkenyl, or alkynyl group. Exemplary heteroatom groups that may be included in these groups include, but are not limited to, -O-, -S-, -OO-, -SS-, -OS-, -NR 501 R 502 -, =NN=, -N=N-, -N=N-NR 503 R 404 , -PR 505 -, -P(O)2-, -POR 506 -, -OP(O)2-, -SO-, -SO2-, -SnR 507 R 508 - etc., R 501 , R 502 , R 503 , R 504 , R 505 , R 506 , R 507 and R 508 is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, or substituted heteroarylalkyl.

[0033] "Heteroaryl," by itself or as part of another substituent, refers to a monovalent heteroaromatic group derived by the removal of a hydrogen atom from a single atom of a parent heteroaromatic ring system, as defined herein. Typical heteroaryl groups include, but are not limited to, groups derived from acridine, β-carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like. In some embodiments, heteroaryl groups contain 5 to 20 ring atoms (5-20 membered heteroaryl). In other embodiments, heteroaryl groups contain 5 to 10 ring atoms (5-10 membered heteroaryl). Exemplary heteroaryl groups include those derived from furan, thiophene, pyrrole, benzothiophene, benzofuran, benzimidazole, indole, pyridine, pyrazole, quinoline, imidazole, oxazole, isoxazole, and pyrazine.

[0034] "Heteroarylalkyl" by itself or as part of another substituent means an alkyl group having a carbon atom, typically a terminal or sp 3" refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom is replaced with a heteroaryl group. Where specific alkyl moieties are intended, the nomenclature heteroarylalkanyl, heteroarylalkenyl, and / or heteroarylalkynyl is used. In some embodiments, the heteroarylalkyl group is a 6- to 21-membered heteroarylalkyl, e.g., the alkanyl, alkenyl, or alkynyl portion of the heteroarylalkyl is (C1-C6)alkyl and the heteroaryl portion is a 5- to 15-membered heteroaryl. In other embodiments, the heteroarylalkyl is a 6- to 13-membered heteroarylalkyl, e.g., the alkanyl, alkenyl, or alkynyl portion is (C1-C3)alkyl and the heteroaryl portion is a 5- to 10-membered heteroaryl.

[0035] "Parent Aromatic Ring System" refers to an unsaturated cyclic or polycyclic ring system having a conjugated π-electron system. Specifically included within the definition of "parent aromatic ring system" are fused ring systems in which one or more of the rings is aromatic and one or more of the rings is saturated or unsaturated, such as fluorene, indane, indene, phenalene, etc. Exemplary parent aromatic ring systems include, but are not limited to, aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the like.

[0036] "Parent Heteroaromatic Ring System" refers to a parent aromatic ring system in which one or more carbon atoms (and optionally any associated hydrogen atoms) are each independently replaced with the same or different heteroatom. Typical heteroatoms replacing carbon atoms include, but are not limited to, N, P, O, S, Si, etc. Specifically included within the definition of "parent heteroaromatic ring system" are fused ring systems in which one or more of the rings is aromatic and one or more of the rings is saturated or unsaturated, e.g., benzodioxanes, benzofurans, chromans, chromenes, indoles, indolines, xanthenes, etc. Exemplary parent heteroaromatic ring systems include, but are not limited to, arsindole, carbazole, β-carboline, chroman, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizidine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like.

[0037] "Preventing" or "prevention" refers to reducing the risk of acquiring a disease or disorder (i.e., at least one clinical symptom of the disease does not occur in a patient who may be exposed to or susceptible to the disease, but who has not yet experienced or displayed symptoms of the disease). The application of a therapy to prevent or prevent a disease or disorder is known as "prophylaxis." In some embodiments, the compounds provided herein provide superior prevention because they have fewer long-term side effects over an extended period of time.

[0038] "Salt" refers to a salt of a compound that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or salts of acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2 or (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or salts formed when coordinated with an organic base, e.g., ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, etc.

[0039] "Substituted," when used to modify a particular group or radical, means that one or more hydrogen atoms of the particular group or radical are each replaced, independently of one another, with the same or different substituents. Substituents useful for replacing saturated carbon atoms of a particular group or radical include, but are not limited to, -R a , halo, -O-, =O, -OR b , -SR b , -S - , =S, -NR c R c , =NR b , =N-OR b , trihalomethyl, -CF3, -CN, -OCN, -SCN, -NO, -NO2, -N-OR b、-N-NR c R c 、-NR b S(O)2R b 、=N2、-N3、-S(O)2R b 、-S(O)2NR b R b 、-S(O)2O - 、-S(O)2OR b 、-OS(O)2R b 、-OS(O)2O - 、-OS(O)2OR b 、-OS(O)2NR c NR c 、--P(O)(O - )2、-P(O)(OR b )(O - )、-P(O)(OR b )(OR b )、-C(O)R b 、-C(O)NR b -OR b -C(S)R b 、-C(NR b )R b 、-C(O)O - 、-C(O)OR b 、-C(S)OR b 、-C(O)NR c R c 、-C(NR b )NR c R c 、-OC(O)R b 、-OC(S)R b 、-OC(O)O - 、-OC(O)OR b 、-OC(O)NR c R c 、-OC(NCN)NR c R c -OC(S)OR b 、-NR b C(O)R b 、-NR b C(S)R b 、-NR b C(O)O - 、-NR b C(O)OR b 、-NR b C(NCN)OR b, -NR b S(O)NR c R c , -NR b C(S)OR b , -NR b C(O)NR c R c , -NR b C(S)NR c R c , -NR b C(S)NR b C(O)R a , -NR b S(O)2OR b , -NR b S(O)2R b , -NR b C(NCN)NR c R c , -NR b C(NR b )R b and -NR b C(NR b )NR c R c R a are independently alkyl, heteroalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; each R b are independently hydrogen, R a , substituted alkyl, substituted heteroalkyl, substituted aryl, substituted arylalkyl, substituted heteroaryl, and substituted heteroarylalkyl; each R c is independently R b or alternatively, two R c taken together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered cycloheteroalkyl, substituted cycloheteroalkyl, or cycloheteroalkyl fused to an aryl group which may optionally contain 1 to 4 additional heteroatoms, which may be the same or different, selected from the group consisting of O, N, and S. Particular examples include -NR c R c is intended to include -NH2, -NH-alkyl, N-pyrrolidinyl, and N-morpholinyl.

[0040] Similarly, useful substituents for replacing unsaturated carbon atoms of particular groups or radicals include, but are not limited to, -R a , halo, -O - , -OR b , -SR b , -S - , -NR c R c , trihalomethyl, -CF3, -CN, -OCN, -SCN, -NO, -NO2, -N3, -S(O)2R b , -S(O)2O - , -S(O)2OR b , -OS(O)2R b , -OS(O)2O - , -OS(O)2OR b , -P(O)(O - )2, -P(O)(OR b )(O - ), -P(O)(OR b )(OR b ), -C(O)R b , -C(S)R b , -C(NR b )R b , -C(O)O - , -C(O)OR b , -C(S)OR b , -C(O)NR c R c , -C(NR b )NR c R c , -OC(O)R b , -OC(S)R b , -OC(O)O - , -OC(O)OR b , -OC(S)OR b , -OC(O)NR c R c , -OS(O)2NR c NR c , -NR b C(O)R b , -NR b C(S)R b , -NR b C(O)O - , -NR b C(O)OR b , -NR bS(O)2OR a , -NR b S(O)2R a , -NR b C(S)OR b , -NR b C(O)NR c R c , -NR b C(NR b )R b and -NR b C(NR b )NR c R c R a , R b and R c is as defined above.

[0041] Useful substituents for substituting nitrogen atoms on heteroalkyl and cycloheteroalkyl groups include, but are not limited to, -R a , -O - , -OR b , -SR b , -S - , -NR c R c , trihalomethyl, -CF3, -CN, -NO, -NO2, -S(O)2R b , -S(O)2O - , -S(O)2OR b , -OS(O)2R b , -OS(O)2O - , -OS(O)2OR b , -P(O)(O - )2, -P(O)(OR b )(O - ), -P(O)(OR b )(OR b ), -C(O)R b , -C(S)R b , -C(NR b )R b , -C(O)OR b , -C(S)OR b , -C(O)NR c R c , -C(NR b )NR c R c , -OC(O)R b, -OC(S)R b , -OC(O)OR b , -OC(S)OR b , -NR b C(O)R b , -NR b C(S)R b , -NR b C(O)OR b , -NR b C(S)OR b , -NR b C(O)NR c R c , -NR b C(NR b )R b and -NR b C(NR b )NR c R c R a , R b and R c is as defined above.

[0042] Substituents from the above list that are useful for replacing other particular groups or atoms will be apparent to those skilled in the art.

[0043] Substituents employed to substitute a particular group may generally be further substituted with one or more of the same or different groups selected from the various groups identified above.

[0044] compound The present invention provides novel piperidinyl nociceptin receptor ligands useful in the treatment of neurological diseases and conditions, which ligands mediate the negative effects of the conditions, including, for example, acute and chronic pain, substance abuse / dependence, alcoholism, anxiety, depression, sleep disorders, gastrointestinal disorders, renal disorders, cardiovascular diseases, and Parkinson's disease.

[0045] In some embodiments, structural formula (I): [ka] (Wherein A is [ka] and; B is hydrogen; or alternatively, A and B are absent and the carbon atoms to which they are attached are [ka] is the carbon atom adjacent to the amide carbonyl atom of; R and R together with the carbon atoms to which they are attached form an aryl, substituted aryl, heteroaryl, or substituted heteroaryl; X is hydrogen, -C=NOR, -C(O)NR, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, or substituted heteroarylalkyl; Y is hydrogen, -C=NOR, -C(O)NR, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, or substituted heteroarylalkyl; T is =NR 10 ;=CR 11 R 12 -, -NR 13 R 14 R3 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, or substituted heteroarylalkyl; provided that R1 and R2 form a phenyl ring and L is [ka] where R3 is not hydrogen or methyl; R4 is hydrogen, alkyl, or substituted alkyl; R5 is hydrogen, alkyl, or substituted alkyl; and R6 is hydrogen, alkyl, substituted alkyl, or OR. 15 R7 is hydrogen, alkyl, or substituted alkyl; R8 and R9 are independently hydrogen, alkyl, or substituted alkyl; R 10 is hydrogen, alkyl, substituted alkyl, -OR 16 or -NR 17 R 18 and;R 11 is hydrogen, alkyl, substituted alkyl, -C(O)R 19 or -CN; R 12 is hydrogen, -C(O)R 20 or -CN; R 13 is hydrogen or -C(O)R 21 and;R 14 is hydrogen or -C(O)R 22 However, R 13 and R 14 and R are not both hydrogen; 15 is hydrogen, alkyl or substituted alkyl, and R 16 is hydrogen, alkyl or substituted alkyl; R 17 is hydrogen or -C(O)R 23 and;R 18 is hydrogen or -C(O)R 24 and;R 19 and R 20 independently -NR 25 R 26 , -OR 27 , alkyl, substituted alkyl, heteroalkyl, or substituted heteroalkyl; R 21 and R 22 independently -NR 28 R 29 , -OR 30 , alkyl, substituted alkyl, heteroalkyl, or substituted heteroalkyl; R 23 and R 24 are independently alkyl or substituted alkyl; R 25 , R 26 , R 27 , R 28 , R29 and R 30 are independently hydrogen, alkyl, or substituted alkyl; L is (C3-C8)cycloalkyl, (C3-C8)substituted cycloalkyl, (C3-C8)cycloheteroalkyl, (C3-C8)substituted cycloheteroalkyl, [ka] or a salt, hydrate or solvate thereof.

[0046] In some embodiments, R 1 and R 2 together with the carbon atom to which they are attached form a phenyl, substituted phenyl, pyridyl, or substituted pyridyl.

[0047] In some embodiments, L is (C3-C8)cycloalkyl, (C3-C8)substituted cycloalkyl, or (C3-C8)cycloheteroalkyl. [ka] wherein n is 0, 1 or 2, and K is -NR 31 - or -O-, and R 31 is hydrogen, alkyl, or substituted alkyl. In yet another embodiment, L is a substituted cyclohexyl group. In yet another embodiment, L is [ka] wherein Z is alkyl, substituted alkylaryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, or substituted heteroarylalkyl; and U is hydrogen, alkyl, or absent. In yet another embodiment, Z is alkyl, substituted alkyl, heteroalkyl, or substituted heteroalkyl. In yet another embodiment, Z is [ka] and U is hydrogen. In yet another embodiment, Z is methyl and U is methyl. In yet another embodiment, Z is [ka] and U does not exist.

[0048] In some embodiments, A is [ka] In another embodiment, R1 and R2 form a phenyl, substituted phenyl, pyridyl, or substituted pyridyl. In yet another embodiment, a compound represented by Structural Formula (II): [ka] (Wherein, D is —CH— or —N—, and R 32 is alkyl, halo, -OR 33 , -NHR 34 , -CF3 or -CN; n is an integer of 0 to 4; R 33 is hydrogen, alkyl, -(CO)NR 35 R 36 or -SO2NR 37 R 38 and;R 34 , R 35 , R 36 , R 37 and R 38are independently hydrogen or alkyl. In yet another embodiment, X is hydrogen, -C=NOR4, -C(O)NR5R6, alkyl, substituted alkyl, aryl, substituted aryl, heteroalkyl, or substituted heteroalkyl; and Y is hydrogen, -C=NOR7, -C(O)NR8R9, alkyl, substituted alkyl, aryl, substituted aryl, heteroalkyl, or substituted heteroalkyl. In yet another embodiment, X is hydrogen; and Y is -C=NOR7, -C(O)NR8R9, alkyl, substituted alkyl, aryl, substituted aryl, heteroalkyl, or substituted heteroalkyl. In yet another embodiment, X is -C=NOR4, -C(O)NR5R6, alkyl, substituted alkyl, aryl, substituted aryl, heteroalkyl, or substituted heteroalkyl; and Y is hydrogen. In yet another embodiment, X is -C=NOR4, -C(O)NR5R6, alkyl, substituted alkyl, aryl, substituted aryl, heteroalkyl, substituted heteroalkyl; and Y is -C=NOR7, -C(O)NR8R9, alkyl, substituted alkyl, aryl, substituted aryl, heteroalkyl, or substituted heteroalkyl.

[0049] In some embodiments, A is [ka] In another embodiment, R1 and R2 form a phenyl, substituted phenyl, pyridyl, or substituted pyridyl. In yet another embodiment, a compound represented by Structural Formula (III): [ka] (wherein E is —CH— or —N—; R 39 is alkyl, halo, -OR 40 , -NHR 41 , -CF3 or -CN; o is an integer of 0 to 4; R 40 is hydrogen, alkyl, -(CO)NR 42 R 43 or -SO2NR 44 R 45 and;R 41 , R 42 , R 43, R 44 and R 45 are independently hydrogen or alkyl.

[0050] In some embodiments, A and B are absent and the carbon atoms to which they are attached are: [ka] In another embodiment, R and R form a phenyl, substituted phenyl, pyridyl, or substituted pyridyl. In yet another embodiment, R is a carbon atom adjacent to the amide carbonyl atom of Structural Formula (IV): [ka] (Wherein J is —CH— or —N—, R 46 is alkyl, halo, -OR 47 , -NHR 48 , -CF3 or -CN; p is an integer of 0 to 4; R 47 is hydrogen, alkyl, -(CO)NR 49 R 50 , -SO2NR 51 R 52 and;R 48 , R 49 , R 50 , R 51 and R 52 are independently hydrogen or alkyl.

[0051] Table 1 shows compounds of structural formula (II): In some embodiments, the 1,4-substituents on the cyclohexyl ring are cis to each other.

[0052] [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] Table 1-5 Table 1-6 Table 1-7 Table 1-8 Table 1-9 Table 1-10 Table 1-11 Table 1-12 Table 1-13 Table 1-14 Table 1-15 Table 1-16 Table 1-17 Table 1-18 Table 1-19 Table 1-20 Table 1-21 [Table 1-22] [Table 1-23] [Table 1-24] [Table 1-25] [Table 1-26] [Table 1-27] [Table 1-28] [Table 1-29] [Table 1-30] [Table 1-31] [Table 1-32] [Table 1-33] [Table 1-34]

[0053] Table 2 shows compounds of structural formula (III): In some embodiments, the 1,4-substituents on the cyclohexyl ring are cis to each other.

[0054] [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10] [Table 2-11] [Table 2-12] [Table 2-13]

[0055] Table 3 shows compounds of structural formula (IV): In some embodiments, the 1,4-substituents on the cyclohexyl ring are cis to each other.

[0056] [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] [Table 3-8] [Table 3-9] [Table 3-10] [Table 3-11] [Table 3-12] [Table 3-13] [Table 3-14]

[0057] Preparation of compounds Piperidinyl-containing nociceptin receptor compounds of Formula (I), as well as embodiments of Formula (II), Formula (III), and Formula (IV), can be synthesized via a number of synthetic routes, as will be appreciated by those skilled in the art. Exemplary methods for synthesizing compounds of Formula (II) are shown in Figures 1-6 and 10 and described below in Examples 1-6 and 10. Table 1 lists the synthesis of compounds of Formula II. 1 1 H NMR or TLC data is also provided.

[0058] Exemplary methods for synthesizing compounds of formula (III) are shown in Figures 7 and 8 and described below in Examples 7 and 8. For compounds of formula (III), Table 2 lists the methods for synthesizing those compounds. 1 1 H NMR or TLC data is provided.

[0059] Exemplary routes to compounds of formula (IV) are shown in Figure 9 and described below in Example 9. For compounds of formula (IV), Table 3 provides the following where indicated: 1 H NMR data is provided.

[0060] Compositions and Methods of Administration The compositions provided herein comprise a therapeutically effective amount of one or more of the compounds provided herein useful for the prevention, treatment, or amelioration of one or more symptoms of a disease or disorder described herein, and a vehicle. Vehicles suitable for administering the compounds provided herein include any carrier known to those skilled in the art to be suitable for the particular mode of administration. In addition, the compounds may be formulated as the sole active ingredient in the composition or may be combined with other active ingredients.

[0061] The compositions comprise one or more compounds provided herein. In some embodiments, the compounds are prepared into suitable formulations, such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained-release formulations, or elixirs for oral administration, or sterile solutions or suspensions for parenteral administration, as well as topical administration, transdermal administration, and oral inhalation via nebulizers, pressurized metered-dose inhalers, and dry powder inhalers. In some embodiments, the compounds described above are prepared into compositions using techniques and procedures well known in the art (see, e.g., Ansel, Introduction to Pharmaceutical Dosage Forms, Seventh Edition (1999)).

[0062] In the compositions, an effective concentration of one or more compounds or derivatives thereof is mixed with a suitable vehicle. The compounds may be derivatized as the corresponding salts, esters, enol ethers or esters, acetals, ketals, orthoesters, hemiacetals, hemiketals, acids, bases, solvates, ion pairs, hydrates, or prodrugs prior to preparation, as described above. The concentration of the compounds in the compositions is effective to deliver an amount that, upon administration, will treat, prevent, or ameliorate one or more symptoms of the diseases or disorders described herein. In some embodiments, the compositions are prepared for single-dose administration. To prepare the compositions, a weight fraction of the compounds is dissolved, suspended, dispersed, or otherwise mixed in a selected vehicle at an effective concentration to alleviate, prevent, or ameliorate one or more symptoms of the condition being treated.

[0063] The active compound is contained in the vehicle in an amount sufficient to provide a therapeutically useful effect without undesirable side effects to the treated patient. The therapeutically effective concentration can be predicted empirically by testing the compound in in vitro and in vivo systems well known to those skilled in the art and then extrapolating it to a human dosage. The human dosage is then typically fine-tuned and titrated in clinical trials to determine the response.

[0064] The concentration of active compound in the composition will depend on absorption, inactivation, and excretion rates of the active compound, the physicochemical properties of the compound, the administration schedule, and the amount administered, as well as other factors known to those skilled in the art, for example, the amount delivered will be sufficient to ameliorate one or more of the symptoms of the disease or disorder described herein.

[0065] If a compound has insufficient solubility, methods for solubilizing the compound can be used, such as the use of liposomes, prodrugs, complexation / chelation, nanoparticles, or emulsions, or tertiary templating. Such methods are known to those skilled in the art and include, but are not limited to, the use of cosolvents such as dimethyl sulfoxide (DMSO), the use of surfactants or surface modifiers such as TWEEN®, the use of complexing agents such as cyclodextrins, or dissolution by enhanced ionization (i.e., dissolution in aqueous sodium bicarbonate). Derivatives of the compound, such as prodrugs of the compound, can also be used to prepare effective compositions.

[0066] After mixing or addition of the compound(s), the resulting mixture may be a solution, suspension, emulsion, etc. The form of the resulting mixture will depend on several factors, including the intended mode of administration and the solubility of the compound in the selected vehicle. The effective concentration will be sufficient to ameliorate the symptoms of the disease, disorder, or condition being treated and can be empirically determined.

[0067] Compositions are provided for administration to indicated humans and animals in suitable dosage forms, such as dry powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), nebulizers, tablets, capsules, pills, sublingual tapes / bioerodible strips, tablets or capsules, powders, granules, lozenges, lotions, ointments, suppositories, fast dissolves, transdermal patches or other transdermal application devices / formulations, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions, containing an appropriate amount of the compound or its derivatives. The therapeutically active compounds and their derivatives are, in some embodiments, prepared and administered in unit-dosage or multi-dosage forms. As used herein, unit-dosage form refers to physically discrete units suitable for human and animal subjects, individually packaged as known in the art. Each unit dose contains a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required vehicle. Examples of unit-dosage forms include ampoules and syringes, and individually packaged tablets or capsules. A unit-dosage form may be administered in portions or multiples thereof. A multiple-dosage form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dosage form. Examples of multiple-dosage forms include vials, bottles of tablets or capsules, or bottles of pints or gallons. Thus, a multiple-dosage form is a plurality of unit doses that are not segregated in packaging.

[0068] Liquid compositions can be prepared, for example, by dissolving, dispersing, or otherwise mixing the active compound(s) defined above and, if necessary, auxiliary agents in a vehicle such as, for example, water, saline, aqueous dextrose, glycerol, glycol, ethanol, etc., thereby forming a solution or suspension, colloidal dispersion, emulsion, or liposomal preparation. If desired, the composition to be administered can also contain small amounts of non-toxic auxiliary substances such as wetting agents, emulsifiers, solubilizing agents, pH buffering agents, and the like, for example, acetate salts, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents.

[0069] Actual methods for preparing these dosage forms will be known, or apparent, to those skilled in the art; see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15th Edition, 1975 or later editions.

[0070] Dosage forms or compositions can be prepared containing 0.005% to 100% of the active ingredient, with the remainder consisting of the vehicle or carrier. Methods for preparing these compositions are known to those skilled in the art. Contemplated compositions may contain 0.001% to 100%, in one embodiment 0.1 to 95%, and in another embodiment 0.4 to 10% of the active ingredient.

[0071] In certain embodiments, the composition is a lactose-free composition containing excipients, which are well known in the art and are listed, for example, in US Pharmacopeia (USP) 25-NF20 (2002). Generally, lactose-free compositions contain an active ingredient, a binder / filler, and a comparable amount of a lubricant. A particular lactose-free dosage form contains the active ingredient, microcrystalline cellulose, pregelatinized starch, and magnesium stearate.

[0072] Because water can accelerate the decomposition of some compounds, anhydrous compositions and dosage forms containing active ingredients are also provided. For example, the addition of water (e.g., 5%) is widely accepted as a means of simulating long-term storage to determine properties such as shelf life or stability of a formulation over time. See, for example, Jens T. Carstensen, Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, NY, 1995, pp. 379-80. In fact, water and heat accelerate the decomposition of some compounds. Therefore, the effect of water on a formulation can be very important, since moisture and / or humidity are commonly encountered during the manufacture, handling, packaging, storage, shipping, and use of formulations.

[0073] Anhydrous compositions and dosage forms provided herein can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.

[0074] Anhydrous compositions should be prepared and stored so as to maintain their anhydrous nature. Accordingly, anhydrous compositions are generally packaged using materials known to prevent exposure to water so that they can be included in suitable formulary kits. Examples of suitable packaging materials include, but are not limited to, hermetically sealed foils, plastics, unit-dose containers (e.g., vials), blister packs, and strip packs.

[0075] Oral dosage forms are either solid, gel, or liquid. Solid dosage forms are tablets, capsules, granules, and bulk powders. Types of oral tablets include compressed tablets, chewable lozenges, and tablets that may be enteric-coated, sugar-coated, or film-coated. Capsules may be hard or soft gelatin capsules, while granules and powders may be provided in non-effervescent or effervescent form in combination with other ingredients known to those skilled in the art.

[0076] In certain embodiments, the formulation is in a solid dosage form, such as a capsule or tablet. Tablets, pills, capsules, lozenges, etc. may contain one or more of the following ingredients, or compounds of a similar nature: binders, lubricants, diluents, glidants, tablet disintegrants, colorants, sweeteners, flavorings, wetting agents, enteric coatings, film coatings, and release-modifying agents. Examples of binders include microcrystalline cellulose, methylparaben, polyalkylene oxides, tragacanth gum, glucose solution, acacia mucilage, gelatin solution, molasses, polyvinylpyrrolidone, povidone, crospovidone, sucrose, and starch and starch derivatives. Lubricants include talc, starch, magnesium / calcium stearate, lycopodium, and stearic acid. Diluents include, for example, lactose, sucrose, trehalose, lysine, leucine, lecithin, starch, kaolin, salt, mannitol, and dicalcium phosphate. Glidants include, but are not limited to, colloidal silicon dioxide. Disintegrants include, for example, croscarmellose sodium, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar, and carboxymethylcellulose. Coloring agents include, for example, any of the approved certified water-soluble FD and C dyes, mixtures thereof; and water-insoluble FD and C dyes suspended on alumina hydrate, as well as high-grade colorants or anti-counterfeit color / opalescence additives known to those skilled in the art. Sweetening agents include sucrose, lactose, mannitol, and artificial sweeteners such as saccharin, as well as any number of spray-dried flavoring agents. Flavoring agents include natural flavors extracted from plants such as fruits, and synthetic blends of compounds that produce a pleasant sensation or mask unpleasant tastes, such as, but not limited to, peppermint and methyl salicylate. Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Enteric coatings include fatty acids, fats, waxes, shellac, ammoniated shellac, and cellulose acetate phthalate. Film coatings include hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate.Release-modifying agents include polymers such as the Eudragit® series and cellulose esters.

[0077] The compound or its derivative may be provided in a composition that protects the compound or its derivative from the acidic environment of the stomach. For example, the composition may be prepared with an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine. The composition may also be prepared in combination with an antacid or other such ingredient.

[0078] When the dosage unit is a capsule, the capsule may contain a liquid carrier such as fatty oil in addition to the above-mentioned materials. In addition, the dosage unit may contain various other materials that modify the physical form of the dosage unit, such as coatings of sugar and other enteric agents. The compound may also be administered as a component of an elixir, suspension, syrup, wafer, sprinkle, chewing gum, etc. The syrup may contain, in addition to the active compound, sucrose as a sweetener, and certain preservatives, dyes, coloring agents, and flavoring agents.

[0079] The active ingredients may also be mixed with other active ingredients that do not impair the desired action, or with ingredients that supplement the desired action, such as anthraquinone, H2 blockers, and diuretics. The active ingredient is a compound described herein or a derivative thereof. Higher concentrations of the active ingredient, up to about 98% by weight, may be included.

[0080] In all embodiments, tablet and capsule formulations may be coated as known to those skilled in the art to modify or sustain dissolution of the active ingredient. Thus, for example, they may be coated with conventional enterically digestible coatings such as phenylsalicylate, waxes and cellulose acetate phthalate.

[0081] Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and / or suspensions reconstituted from non-effervescent granules, and effervescent preparations reconstituted from effervescent granules. Aqueous solutions include, for example, elixirs and syrups. Emulsions are either oil-in-water or water-in-oil.

[0082] Elixirs are clear, sweetened, hydroalcoholic preparations. The vehicle used in elixirs includes a solvent. Syrups are concentrated aqueous solutions of a sugar, such as sucrose, and may contain a preservative. Emulsions are two-phase systems in which one liquid is dispersed in the form of small globules throughout another liquid. The carriers used in emulsions are non-aqueous liquids, emulsifiers, and preservatives. Suspensions use suspending agents and preservatives. Acceptable substances used in non-effervescent granules to be reconstituted into a liquid oral dosage form include diluents, sweeteners, and wetting agents. Acceptable substances used in effervescent granules to be reconstituted into a liquid oral dosage form include organic acids and a carbon dioxide source. Coloring and flavoring agents are used in all of the above dosage forms.

[0083] Solvents include glycerin, sorbitol, ethyl alcohol, and syrup. Examples of preservatives include glycerin, methyl and propylparaben, benzoic acid, sodium benzoate, and alcohol. Examples of non-aqueous liquids used in emulsions include mineral oil and cottonseed oil. Examples of emulsifying agents include gelatin, acacia, tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate. Suspending agents include sodium carboxymethylcellulose, pectin, tragacanth, Veegum, and acacia. Sweetening agents include sucrose, syrup, glycerin, and artificial sweeteners such as saccharin. Humectants include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Organic acids include citric acid and tartaric acid. Carbon dioxide sources include sodium bicarbonate and sodium carbonate. Coloring agents include any of the approved certified water-soluble FD and C dyes, and mixtures thereof. Flavoring agents include natural flavors extracted from plants such as fruits, and synthetic blends of compounds which produce a pleasant taste sensation.

[0084] For solid dosage forms, solutions or suspensions, for example, in propylene carbonate, vegetable oils, or triglycerides, are in some embodiments encapsulated in gelatin capsules. Such solutions, and their formulation and encapsulation, are disclosed in U.S. Patent Nos. 4,328,245; 4,409,239; and 4,410,545. For liquid dosage forms, the solutions, for example, in polyethylene glycol, are diluted with a sufficient quantity of a liquid vehicle, for example, water, to be easily measured for administration.

[0085] Alternatively, liquid or semisolid oral formulations can be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g., propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells. Other useful formulations include those shown in U.S. Reissue Patent No. 28,819 and U.S. Patent No. 4,358,603. Briefly, such formulations include, but are not limited to, a compound provided herein, a dialkylated mono- or polyalkylene glycol, including, but not limited to, 1,2-dimethoxyethane, diglyme, triglyme, tetraglyme, polyethylene glycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether (where 350, 550, and 750 refer to the approximate average molecular weight of the polyethylene glycol), and one or more antioxidants, such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarin, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, thiodipropionic acid and its esters, and dithiocarbamates.

[0086] Other formulations include, but are not limited to, aqueous alcoholic solutions containing acetals. The alcohols used in these formulations are any water-miscible solvents containing one or more hydroxyl groups, including, but not limited to, propylene glycol and ethanol. Acetals include, but are not limited to, di(lower alkyl) acetals of lower alkyl aldehydes, such as acetaldehyde diethyl acetal.

[0087] In some embodiments, parenteral administration, characterized by injection, either subcutaneously, intramuscularly, or intravenously, is also contemplated herein. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Injectables, solutions, and emulsions also contain one or more excipients. Suitable excipients are, for example, water, saline, dextrose, glycerol, or ethanol. In addition, if desired, the administered composition may also contain minor amounts of nontoxic auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, and cyclodextrins.

[0088] Implantation of a delayed-release or sustained-release system to maintain a constant level of dosage (see, e.g., U.S. Pat. No. 3,710,795) is also contemplated herein. Briefly, the compounds provided herein are dispersed in a solid inner matrix, e.g., a hydrophilic polymer such as polymethyl methacrylate, polybutyl methacrylate, plasticized or unplasticized polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymer, silicone rubber, polydimethylsiloxane, silicone carbonate copolymer, hydrogels of esters of acrylic and methacrylic acid, collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate, which is then coated with an outer polymeric membrane, e.g., polyethylene, polypropylene, polypropylene copolymer ... The parenteral composition is surrounded by a polymeric membrane that is insoluble in body fluids, and is insoluble in body fluids. The compound diffuses through the outer polymeric membrane in a release rate-controlling step. The percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature of the composition, as well as the activity of the compound and the needs of the subject.

[0089] Parenteral administration of the composition includes intravenous, subcutaneous, and intramuscular administration. Formulations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products (including subcutaneous tablets) such as lyophilized powders ready to be combined with a solvent immediately before use, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle immediately before use, and sterile emulsions. The solutions can be either aqueous or non-aqueous.

[0090] If administered intravenously, suitable carriers include saline or phosphate buffered saline (PBS), and solutions containing thickening agents and solubilizing agents such as dextrose, polyethylene glycol, and polypropylene glycol, and mixtures thereof.

[0091] Vehicles used in parenteral formulations include aqueous vehicles, non-aqueous vehicles, antibacterial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other substances.

[0092] Examples of aqueous vehicles include sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection, dextrose and lactose Ringer's injection. Non-aqueous parenteral vehicles include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil, and peanut oil. Parenteral formulations packaged in multi-dose containers require the addition of bacteriostatic or fungistatic concentrations of antibacterial agents, including phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride, and benzethonium chloride. Isotonic agents include sodium chloride and dextrose D-glucose. Buffers include phosphates and citrates. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspending and dispersing agents include sodium carboxymethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Emulsifying agents include polysorbate 80 (Tween® 80). Metal ion sequestering or chelating agents include EDTA. Carriers also include ethyl alcohol, polyethylene glycol, and propylene glycol for water-miscible vehicles; and sodium hydroxide, hydrochloric acid, citric acid, or lactic acid for pH adjustment.

[0093] The concentration of the compound is adjusted so that injection provides an effective amount to produce the desired pharmacological effect. The correct dose depends on the age, weight, body surface area, and condition of the patient or animal, as is known in the art.

[0094] Unit dose parenteral preparations are packaged in an ampoule, vial or syringe with a needle. All preparations for parenteral administration must be sterile, as known and practiced in the art.

[0095] Illustratively, intravenous or intraarterial infusion of a sterile aqueous solution containing an active compound is an effective mode of administration. Another embodiment is a sterile aqueous or oily solution or suspension containing the active material, injected as needed to produce the desired pharmacological effect.

[0096] Injectables are designed for local and systemic administration. In some embodiments, therapeutically effective doses are prepared to contain concentrations of active compound of at least about 0.01% w / w up to about 90% w / w or more, and in certain embodiments, greater than 0.1% w / w, to treat tissue.

[0097] The compound may be suspended in micronized or other suitable form, or may be derivatized to produce a more soluble active product or to produce a prodrug. The form of the resulting mixture will depend on several factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle. The effective concentration will be sufficient to ameliorate the condition and can be empirically determined.

[0098] The active ingredients provided herein can be administered by controlled release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, U.S. Patent Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,639,480; 5,733,566; 5,739,108; 5,891,474; 5,922 ,356; 5,972,891; 5,980,945; 5,993,855; 6,045,830; 6,087,324; 6,113,943; 6,197,350; 6,248,363; 6,264,970; 6,267,981; 6,376,461; 6,419,961; 6,589,548; 6,613,358; 6,699,500 and 6,740,634. Such dosage forms can be used to provide delayed or controlled release of one or more active ingredients using, for example, hydroxypropyl methylcellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or combinations thereof, which provide the desired release profile at various rates. Suitable controlled-release formulations known to those skilled in the art, including those described herein, can be readily selected for use with the active ingredients provided herein.

[0099] All controlled-release agents share a common goal: improved drug therapy over that achieved by their non-controlled counterparts. Ideally, the use of an optimally designed controlled-release formulation in medical treatment is characterized by curing or controlling a medical condition in a minimum amount of time and using a minimum amount of drug substance. Advantages of controlled-release formulations include extended drug activity, reduced dosing frequency, and improved patient compliance. In addition, controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as blood levels of the drug, and thus may affect the occurrence of side (e.g., adverse) effects.

[0100] Most controlled-release formulations are designed to initially release an amount of drug (active ingredient) that rapidly produces the desired therapeutic effect, and then gradually and continuously release other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time. To maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body. The controlled-release of an active ingredient can be affected by various conditions, including, but not limited to, pH, temperature, enzymes, water, or other physiological conditions or compounds.

[0101] In certain embodiments, the agent may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration. In some embodiments, a pump may be used (see Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)). In other embodiments, polymeric materials may be used. In other embodiments, a controlled-release system may be placed in the vicinity of the therapeutic target, thereby requiring a very small systemic dose (see, e.g., Goodson, Medical Applications of Controlled Release, vol. 2, pp. 115-138 (1984)). In some embodiments, a controlled-release device is introduced into a subject in close proximity to a site of inappropriate immune activation or a tumor. Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).The active ingredient may be dispersed in a solid inner matrix, such as polymethyl methacrylate, polybutyl methacrylate, plasticized or unplasticized polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymers, silicone rubber, polydimethylsiloxane, silicone carbonate copolymers, hydrophilic polymers such as hydrogels of esters of acrylic and methacrylic acid, collagen, cross-linked polyvinyl alcohol and cross-linked partially hydrolyzed polyvinyl acetate, which is then coated with an outer polymeric membrane, such as polyethylene, polypropylene, polypropylene copolymers ... The active ingredient is surrounded by a polymeric membrane that is insoluble in body fluids, and is insoluble in body fluids. The active ingredient then diffuses through the outer polymeric membrane in a release rate-controlling step. The percentage of the active ingredient contained in such parenteral compositions is highly dependent on its specific nature and the needs of the patient.

[0102] Also of interest herein are lyophilized powders that can be reconstituted for administration as solutions, emulsions, and other mixtures. They can also be reconstituted and prepared as solids or gels.

[0103] Sterile lyophilized powders are prepared by dissolving a compound provided herein, or a derivative thereof, in a suitable solvent. The solvent may contain excipients that improve the stability or other pharmacological components of the powder or a reconstituted solution prepared from the powder. Excipients that may be used include, but are not limited to, antioxidants, buffers, and bulking agents. In some embodiments, the excipient is selected from dextrose D-glucose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose, and other suitable substances. The solvent may contain a buffer such as citrate, sodium or potassium phosphate, or other such buffers at approximately neutral pH, or other such buffers known to those of skill in the art. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those of skill in the art provides the desired formulation. In some embodiments, the resulting solution may be dispensed into vials for lyophilization. Each vial may contain a single dose or multiple doses of the compound. The lyophilized powder may be stored under appropriate conditions, such as at about 4°C to room temperature.

[0104] Resuspension of this lyophilized powder with water for injection provides a formulation for parenteral administration. For resuspension, the lyophilized powder is added to sterile water or other suitable carrier. The exact amount depends on the selected compound. Such an amount can be determined empirically.

[0105] Topical mixtures are prepared as described for local and systemic administration. The resulting mixture may be a solution, suspension, emulsion, etc., and is prepared as a cream, gel, ointment, emulsion, solution, elixir, lotion, suspension, tincture, paste, foam, aerosol, douche, spray, suppository, bandage, skin patch, or any other formulation suitable for topical administration.

[0106] The compound or its derivative may be prepared as an aerosol for topical application, e.g., by inhalation (see, e.g., U.S. Pat. Nos. 4,044,126, 4,414,209, and 4,364,923, which describe aerosols for the delivery of steroids useful in the treatment of inflammatory diseases, particularly asthma). These formulations for administration to the respiratory tract may be in the form of an aerosol or solution for a nebulizer, or as an ultrafine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such cases, the particles of the formulation will have a mass median diameter of less than 5 micrometers in some embodiments, and less than 10 micrometers in other embodiments.

[0107] Oral inhalation formulations of the compound or derivative suitable for inhalation include metered dose inhalers, dry powder inhalers, and liquid formulations for administration from a nebulizer or metered dose liquid dispensing system. For both metered dose inhalers and dry powder inhalers, a crystalline form of the compound or derivative is the preferred physical form of the drug to provide longer product stability.

[0108] In addition to particle size reduction methods known to those skilled in the art, crystalline particles of compounds or derivatives can be produced using supercritical fluid processing, which offers significant advantages in the preparation of particles for inhalation delivery by producing inhalable particles of the desired size in a single step (see, e.g., International Publication No. WO 2005 / 025506). The controlled particle size of the microcrystals can be selected to ensure that a significant proportion of the compound or derivative is deposited in the lungs. In some embodiments, these particles have a mass median aerodynamic diameter of about 0.1 to about 10 micrometers, in other embodiments, about 1 to about 5 micrometers, and in yet other embodiments, about 1.2 to about 3 micrometers.

[0109] The inert and non-flammable HFA propellant is selected from HFA 134a (1,1,1,2-tetrafluoroethane) and HFA 227e (1,1,1,2,3,3,3-heptafluoropropane), provided either alone or in a ratio consistent with the density of the crystalline particles of the compound or derivative. The ratio can also be selected to ensure that the product suspension avoids deleterious settling or creaming (which can precipitate irreversible agglomerates) and instead promotes a loosely agglomerated system that disperses easily when shaken. Loosely agglomerated systems are highly regarded for providing optimal stability in pMDI canisters. As a result of the properties of this formulation, it was free of ethanol and surfactants / stabilizers.

[0110] The compounds may be prepared for local or topical application, for example, in the form of gels, creams, and lotions for topical application to the skin and mucous membranes, for example, in the eyes, and for application to the eye or intrathecal or intrathecal application. Topical administration is contemplated for transdermal delivery and administration to the eye or mucous membranes, or for inhalation therapy. Nasal solutions of the active compounds may also be administered alone or in combination with other excipients.

[0111] For nasal administration, the formulation may comprise the esterified phosphonate compound dissolved or suspended in a liquid carrier, particularly an aqueous carrier, for aerosol application. The carrier may contain a solubilizing or suspending agent such as propylene glycol, a surfactant, an absorption enhancer such as lecithin or cyclodextrin, or a preservative.

[0112] Solutions, particularly those intended for ophthalmic use, may be prepared as 0.01% to 10% isotonic solutions, pH about 5 to 7.4, with appropriate salts.

[0113] Other routes of administration, such as transdermal patches, including iontophoretic and electrophoretic devices, and rectal administration, are also contemplated herein.

[0114] Transdermal patches, including iontophoretic and electrophoretic devices, are well known to those skilled in the art. For example, such patches are disclosed in U.S. Patent Nos. 6,267,983, 6,261,595, 6,256,533, 6,167,301, 6,024,975, 6,010715, 5,985,317, 5,983,134, 5,948,433 and 5,860,957.

[0115] For example, dosage forms for rectal administration include rectal suppositories, capsules, and tablets for systemic effects. As used herein, a rectal suppository refers to a solid body for insertion into the rectum that melts or softens at body temperature to release one or more pharmacologically or therapeutically active ingredients. The materials used in rectal suppositories are a base or vehicle and an agent that elevates the melting point. Examples of bases include cocoa butter (theobroma oil), glycerin-gelatin, carbowax (polyoxyethylene glycol), and appropriate mixtures of mono-, di-, and triglycerides of fatty acids. Combinations of various bases can be used. Agents that elevate the melting point of suppositories include spermaceti and wax. Rectal suppositories can be prepared by either compression or molding. In one embodiment, the weight of a rectal suppository is approximately 2 to 3 gm. Tablets and capsules for rectal administration are manufactured using the same materials and methods as those for oral administration.

[0116] The compounds or derivatives provided herein may also be formulated to target specific tissues, receptors, or other areas of the subject to be treated.Many of such targeting methods are well known to those skilled in the art.All of such targeting methods are envisioned for use in the compositions of the present invention.Non-limiting examples of targeting methods are described in, for example, U.S. Patent Nos. 6,316,652, 6,274,552, 6,271,359, 6,253,872, 6,139,865, 6,131,570, 6,120,751, 6,071,495, 6,060, See US Pat. Nos. 6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366, 5,900,252, 5,840,674, 5,759,542 and 5,709,874.

[0117] In some embodiments, liposome suspensions, including tissue-targeted liposomes such as tumor-targeted liposomes, may also be suitable as carriers. These can be prepared according to methods known to those skilled in the art. For example, liposome formulations can be prepared as described in U.S. Pat. No. 4,522,811. Briefly, liposomes such as multilamellar vesicles (MLVs) can be formed by drying phosphatidylcholine and phosphatidylserine (7:3 molar ratio) in a flask. A solution of a compound provided herein in phosphate-buffered saline (PBS) lacking divalent cations is added, and the flask is shaken until the lipid film is dispersed. The resulting vesicles are washed to remove unencapsulated compound, pelleted by centrifugation, and resuspended in PBS.

[0118] The compound or derivative may be packaged within the packaging material as a product comprising the packaging material, a compound provided herein or a derivative thereof that is effective in treating, preventing, or ameliorating one or more symptoms of the disease or disorder described above, and a label indicating the compound or composition or derivative thereof is to be used for treating, preventing, or ameliorating one or more symptoms of the disease or disorder described above.

[0119] The products provided herein include packaging materials. Packaging materials for use in packaged products are well known to those skilled in the art. See, for example, U.S. Patent Nos. 5,323,907, 5,052,558, and 5,033,252. Examples of packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for the selected formulation and intended mode of administration and treatment. Numerous formulations of the compounds and compositions provided herein are contemplated for various treatments or prevention of any of the diseases or disorders described herein.

[0120] Dosage When used for the treatment or prevention of infectious diseases, the compounds described herein or pharmaceutical compositions thereof are administered or applied in a therapeutically effective amount. In human treatment, a physician will determine the most appropriate dosage regimen according to preventive or curative treatment, and according to the age, weight, stage of the disease, and other factors specific to the subject being treated. The amount of active ingredient in the formulations provided herein that is effective for the prevention or treatment of infectious diseases will vary depending on the nature and severity of the disease or condition, and the route by which the active ingredient is administered. The frequency and dosage will also vary according to factors specific to each subject, depending on the specific therapy (e.g., therapeutic or prophylactic) administered, the severity of the infection, the route of administration, and the subject's age, physical condition, weight, response, and past medical history.

[0121] Exemplary dosages of the formulations include milligram or microgram amounts of active compound per kilogram of subject (e.g., about 1 microgram / kilogram to about 50 milligrams / kilogram, about 10 micrograms / kilogram to about 30 milligrams / kilogram, about 100 micrograms / kilogram to about 10 milligrams / kilogram, or about 100 micrograms / kilogram to about 5 milligrams / kilogram).

[0122] In some embodiments, a therapeutically effective dosage should produce a serum concentration of the active ingredient of about 0.001 ng / ml to about 50-200 μg / ml. In other embodiments, the composition should provide a daily dosage of about 0.0001 mg to about 70 mg of compound per kilogram of body weight. Unit dosage forms are prepared to provide from about 0.01 mg, 0.1 mg, or 1 mg to about 500 mg, 1000 mg, or 5000 mg, in some embodiments, from about 10 mg to about 500 mg of the active ingredient or combination of essential ingredients per unit dosage form.

[0123] The active ingredient may be administered at once, or may be divided into several smaller doses administered at intervals. It is understood that the exact dosage and duration of treatment can be empirically determined according to the disease being treated, using known testing protocols, or extrapolation from in vivo or in vitro test data or subsequent clinical trials. It should be noted that concentration and dosage values ​​may also vary depending on the severity of the condition being alleviated. It should be further understood that for any particular subject, a specific dosage regimen will need to be adjusted over time according to the individual need and the professional judgment of the person administering and supervising the administration of the composition, and that the concentration ranges set forth herein are merely exemplary and are not intended to limit the scope and practice of the claimed compositions.

[0124] As will be apparent to those skilled in the art, in some cases it may be necessary to use dosages of the active ingredients outside the ranges disclosed herein. Furthermore, it is noted that the clinician or treating physician will know how and when to interrupt, adjust or terminate therapy in relation to the subject response.

[0125] For systemic administration, a therapeutically effective dose can be estimated initially from in vitro assays. For example, a dose can be estimated based on the IC 50 (i.e., the test compound concentration that is lethal in 50% of cell cultures), or IC determined in cell culture 100 Animal models can be formulated to achieve a circulating concentration range that includes the compound (i.e., the concentration of the compound that is lethal in 100% of cell cultures). Such information can be used to more accurately determine useful doses in humans.

[0126] Initial dosages can also be estimated from in vivo data (e.g., animal models) using techniques well known in the art. Those skilled in the art can readily optimize human administration based on animal data.

[0127] Alternatively, the initial dose may be greater than or equal to the IC 50 , MIC and / or IC 100 can be determined from the dosages of known drugs to be administered by comparing the initial doses of known drugs with those of known drugs and adjusting the initial doses accordingly. Optimal dosages can be obtained from these initial values ​​by routine optimization.

[0128] In cases of local administration or selective uptake, the effective local concentration of compound used may not be related to plasma concentration. One skilled in the art will be able to optimize the therapeutically effective local dose without undue experimentation.

[0129] Ideally, a therapeutically effective dose of the compounds described herein will provide a therapeutic effect without causing significant toxicity. Compound toxicity can be assessed in cell culture or experimental animals according to standard pharmaceutical procedures, e.g., LD50 (the dose lethal to 50% of the population) or LD 100 The therapeutic index can be determined by determining the therapeutic effect (the dose lethal to 100% of the population). The dose ratio between toxicity and therapeutic effect is the therapeutic index. Compounds with high therapeutic indices are preferred. Data obtained from these cell culture assays and animal studies can be used to formulate a non-toxic dosage range for use in subjects. The dosage of the compounds described herein lies preferably within a range of circulating concentrations that include the effective dose with little or no toxicity. The dosage may vary within this range depending on the dosage form employed and the route of administration utilized. The correct formulation, route of administration, and dosage can be selected by the individual physician in view of the patient's condition (see, e.g., Fingl et al., 1975, In: The Pharmacological Basis of Therapeutics, Ch. 1, p. 1).

[0130] Therapeutic methods may be repeated intermittently. In certain embodiments, administration of the same formulations provided herein may be repeated, and the administrations may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or 6 months.

[0131] Methods of Use of the Compounds and Compositions The compounds and compositions described herein can be used in a wide variety of applications for treating or preventing neurological conditions and other diseases in a subject. The methods generally involve administering to a subject a therapeutically effective amount of a compound disclosed herein or a pharmaceutical composition thereof.

[0132] The compounds and compositions described herein may be used to treat, for example, pain (e.g., neuropathic pain, sensitization associated with neuropathic pain, and inflammatory pain, sickle cell pain, acute pain), fibromyalgia, migraine; substance abuse or dependence (e.g., nicotine, cocaine, methamphetamine), alcoholism; anxiety, depression (e.g., major depressive disorder), post-traumatic stress disorder, mood disorders, affective disorders (e.g., depression and dysthymia; bipolar disorders, e.g., bipolar depression; mania; seasonal affective disorder; and attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD)), obsessive-compulsive disorder, dizziness, epilepsy, schizophrenia, schizophrenia-related disorders, schizophrenia spectrum disorders, acute schizophrenia, chronic schizophrenia, NOS schizophrenia, schizoid personality disorder, schizotypal personality disorder, delusional disorder, psychosis, psychotic disorder, brief psychotic disorder. Neurological conditions such as shared psychotic disorders, mental disorders resulting from a systemic medical condition, drug-induced psychosis (e.g., cocaine, alcohol, amphetamines), schizoaffective disorder, aggression, delirium, Parkinson's psychosis, excited psychosis, Tourette's syndrome, organic or NOS psychosis, seizures, agitation, behavioral disorders; Alzheimer's disease, Parkinson's disease, dyskinesia, Huntington's disease, dementia; cognitive impairment, cognitive impairment associated with schizophrenia (CIAS), movement disorders, restless limbs syndrome (RLS), multiple sclerosis, sleep disorders, sleep apnea, narcolepsy, excessive daytime sleepiness, jet lag, somnolence side effects from medication, insomnia, eating disorders, sexual dysfunction, hypertension, vomiting, Lesch-Nyhan disease, Wilson's disease, autism, Huntington's chorea, or neurodegenerative diseases such as premenstrual dysphoria.

[0133] Nociceptin receptor compounds can be used to treat or prevent renal diseases and urinary incontinence, including, but not limited to, those characterized by an imbalance in inappropriate antidiuretic hormone secretion, water retention, and / or salt excretion. For example, U.S. Patent No. 6,869,960 discloses a class of spiropiperidine ORL-1 ligands that are said to be therapeutic agents for renal diseases.

[0134] Nociceptin receptor compounds can also be used to treat or prevent cardiovascular diseases, including, but not limited to, systolic hypertension, myocardial infarction, bradycardia, arrhythmia, hypertension, hypotension, thrombosis, anemia, arteriosclerosis, and angina pectoris. For example, U.S. Patent No. 7,241,770 discloses a class of nociceptin agonists that are said to be therapeutic agents for cardiovascular diseases.

[0135] Nociceptin receptor compounds can further be used to treat or prevent gastrointestinal disorders, including but not limited to diarrhea and pain such as in inflammatory bowel disease, Crohn's disease, and inflammatory bowel syndrome.

[0136] The compounds disclosed herein may utilize novel non-dopaminergic targets for the treatment of Parkinson's disease (PD) and its associated dysgenesis. Several studies have revealed the pathogenic role of N / OFQ and NOP receptors in the nigrostriatal pathway affected in PD (see below). The NOP receptor, a G-protein-coupled receptor, is the fourth member of the opioid receptor family, but does not bind known opiates with high affinity (Mollereau et al., FEBS Lett., 1994, 341:33-8). The endogenous ligand for NOP is a 17-amino acid peptide designated N / OFQ. N / OFQ has low affinity for μ, δ, and κ opioid receptors (Gintzler, et al., Eur. J. Pharmacol., 1997, 325:29-34). The N / OFQ-NOP receptor system is widely expressed in brain cortical and subcortical regions, particularly in striatal, pallidum, and substantia nigra (SN) neurons.

[0137] Endogenous N / OFQ contributes to the development of PD symptoms, and N / OFQ levels are elevated in the SNr after dopamine (DA) cell loss or impairment of DA transmission (Marti, et al., Mov. Disord., 2010, 25:1723-32). Such increases are also observed in the CSF of PD patients (Marti et al., 2010); ii) NOP receptor antagonists reverse parkinsonian-like symptoms in neurodegenerative (6-OHDA unilaterally lesioned rats, MPTP-treated mice, and macaques) and functional (reserpine- or haloperidol-treated) models of PD; iii) genetic deletion of the N / OFQ gene protects mice from the neurotoxic effects of MPTP. Mechanistic studies have revealed that the antiparkinsonian effects of NOP antagonists are achieved through normalization of the imbalance between excitatory (GLU) and inhibitory (GABA) inputs to the nigrothalamic neurons caused by striatal DA deafferentation. NOP antagonists also enhance the symptomatic effects of levodopa.

[0138] A NOP receptor agonist (commercially available SCH221510; Varty et al., J. Pharmaco. Exp. Ther., 2008, 326:672-82) attenuated the development of abnormal involuntary movements (AIMs, rodent-associated levodopa-induced dyskinesias (LIDs)) in L-DOPA-exposed dyskinesia-associated rats and nonhuman primates by acting in the striatum, where, in contrast to the SNr, N / OFQ tone was reduced and NOP receptor activity increased after DA cell loss (Marti, M., et al., 2012). This effect could be separated from the typical antikinetic effect of NOP agonists, as the antidyskinetic dose was 100-fold lower than the typical antikinetic dose.

[0139] From a clinical perspective, NOP receptor antagonists disclosed herein may be useful in treating symptoms and neurodegeneration associated with PD, while NOP receptor agonists are effective in treating LID.

[0140] Genetic deletion of the N / OFQ gene protects mice from the neurotoxic effects of MPTP. Mechanistic studies have revealed that the antiparkinsonian effects of NOP antagonists are achieved through normalization of the imbalance between excitatory (GLU) and inhibitory (GABA) inputs to the nigrothalamic neurons caused by striatal DA deafferentation. NOP antagonists also enhance the symptomatic effects of levodopa. Therefore, NOP receptor antagonists may provide symptomatic and neuroprotective effects in PD patients. Meanwhile, NOP receptor agonists have been shown to attenuate the expression of AIMs in dyskinetic rats and nonhuman primates exposed to L-DOPA.

[0141] Nociceptin receptor agonists are known in the art to block the rewarding properties of some common abused drugs, such as morphine, cocaine, amphetamine and alcohol.Administering NOP ligand suppresses basal and drug-stimulated dopamine release in reward areas of rodent brain.The inhibitory effect of NOP agonists on drug reward and the inhibition of drug-induced dopamine release in mesolimbic areas of the brain suggest the usefulness of NOP agonists as a pharmacotherapy for drug abuse.The compounds described herein can be used in the treatment of drug abuse disorders and addiction.

[0142] While other opioid receptors, μ, δ, and κ, have been historically associated with "opioid analgesia," NOP receptors and their agonists and antagonists are just beginning to be recognized as potential analgesics due to emerging data on the antinociceptive activity of NOP ligands in rodent and non-human primate models of acute pain and neuropathic and inflammatory pain (Khroyan et al., Eur. J. Pharmacol., 2009, 610:49-54; Khroyan et al., J. Pharmacol. Exper. Therap., 2011, 339:687-93; Khroyan et al., J. Pharmacol. Exp. Ther., 2007, 320:934-43; Lin and Ko, ACS Chem. Neurosci., 2013, 4:214-24; Toll et al. (Al., J. Pharmacol. Exp. Ther., 2009, 331:954-64). NOP receptors are widely distributed in the central and peripheral nervous system and in the same pain transmission pathways as the other three opioid receptors. However, unlike opioid receptors, the pharmacology of NOP receptors in pain sensation is very different and complex.

[0143] NOP agonists have been shown to have potent antinociceptive effects in rodent models of chronic pain (Khroyan et al., J. Pharmacol. Exp. Therap., 2011, 339:687-93; Sukhtankar et al., J. Pharmacol. Exp. Ther., 2013, 346:11-22). NOP antagonists can enhance the antinociceptive effects of morphine in chronic pain (Khroyan et al., Eur. J. Pharmacol., 2009, 610:49-54). NOP agonists that are effective as analgesics do not exhibit any rewarding effects or abuse potential in rodent models, suggesting that NOP agonists may have advantages as non-addictive analgesics compared to conventional opioids (Khroyan et al., J. Pharmacol. Exp. Ther., 2011, 339:687-93; Toll et al., J. Pharmacol. Exp. Ther., 2009, 331:954-64). The compounds disclosed herein may find use as adjuncts to analgesics (NOP agonists) or opioid pain therapy (NOP antagonists), particularly for chronic, neuropathic, and inflammatory pain conditions.

[0144] All nociceptin receptor ligands have affinity for the NOP receptor and can modulate the receptor's "intrinsic activity (functional efficacy)" over a range of 0% to 100%. NOP ligands that block receptor function with 0% functional efficacy are classified as NOP antagonists. Ligands that activate the receptor with 75% to 100% functional efficacy are classified as NOP agonists. Ligands in between (15% to 75% functional efficacy) are generally classified as NOP partial agonists. The binding affinity of NOP ligands and their functional efficacy (agonist, partial agonist, antagonist) can be tuned by chemical structure modification using various chemical scaffolds, as shown in our previous studies (Zaveri et al., J. Med. Chem., 2004, 47:2973-6; Zaveri, et al., AAPS J., 2005, 7:E345-52; Zaveri et al., "Structure-activity relationships of nociceptin receptor (NOP) ligands and the design of bifunctional NOP / mu opioid receptor-targeted ligands," in Research and Development of Opioid-Related Analgesics, Ko, M.C.; Husbands, S.M., Eds., American Chemical Society, 2013, Chapter 8, pp. 145-160).

[0145] Combination therapy The compounds and compositions disclosed herein can also be used in combination with one or more other active ingredients. In certain embodiments, the compounds can be administered in combination with or sequentially with other therapeutic agents. Such other therapeutic agents include those known for treating, preventing, or ameliorating one or more symptoms associated with drug addiction, pain, neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, psychiatric disorders, renal diseases, gastrointestinal diseases, and cardiovascular diseases.

[0146] It should be understood that any suitable combination of the compounds and pharmaceutical compositions provided herein with one or more of the above therapeutic agents and, optionally, one or more additional pharmacologically active substances is contemplated to be within the scope of the present disclosure. In some embodiments, the compounds and pharmaceutical compositions provided herein are administered before or after one or more additional active ingredients.

[0147] All publications and patents cited herein are incorporated by reference in their entirety. [Example]

[0148] Starting materials and reagents used in the preparation of these compounds were obtained from commercial suppliers such as Sigma-Aldrich (St. Louis, MO), Strem Chemicals (Newburyport, MA), and AK Scientific (Union City, CA). 1 1 H NMR spectra were recorded on a Varian Gemini 300 MHz spectrometer (300 MHz and 75 MHz, respectively) and internally referenced to chloroform at δ 7.27. 1 H NMR data are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant (Hz), integration, and assignment. MS spectra were obtained using a ThermoFinnigan LCQ Duo LC / MS / MS or API 150 EX MS (Applied Biosystems) instrument with an electrospray ionization probe. Thin-layer chromatography was performed on Analtech Uniplate silica gel TLC plates. Flash chromatography was performed using silica gel, Merck grade 9385, 230-400 mesh.

[0149] Example 1: Synthesis of 1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indole (61) and 1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indole-3-carbaldehyde oxime (81) Scheme I illustrates this synthesis.

[0150] Scheme I [ka] Reagents and conditions for Scheme I: a) AcOH, sodium triacetoxyborohydride (STAB), MgSO, DCE, room temperature (General Procedure A); b) i. TFA, CHCl, ii. 4-isopropyl-cyclohexanone, STAB, AcOH, DCE (General Procedure B, 2 steps); c) MnO, CHCl; d) POCl, DMF; and e) NHOH·HCl, NaOAc·3H0, EtOH:H0 (2:1), 110 °C.

[0151] General Procedure A: Reductive Amination with N-Boc Piperidone: The aniline substrate (1.00 equiv.) and N-Boc-piperidone (1.05–1.50 equiv.) were placed in a round-bottom flask. 1,2-DCE (0.25 M) was added, and the mixture was stirred until both components were dissolved. To this solution, MgSO4 (100 wt. % limiting reagent) and glacial AcOH (1.00–2.30 equiv.) were added at ambient temperature, and the solution was stirred for 90 min. At this stage, sodium triacetoxyborohydride (STAB) (1.50–2.30 equiv.) was added. The reaction was allowed to stir at room temperature and was checked by TLC (EtOAc:hexanes). After 1–2 days, the reaction was ≥90% complete by TLC analysis. The reaction was quenched with saturated NaHCO3 (aq.) and stirred until the reaction mixture became basic and effervescence ceased. The biphasic layers were separated and the organic layer was washed twice with HO, brine, dried over MgSO, filtered and concentrated in vacuo to provide a brown oil which was purified by flash chromatography using EtOAc:hexanes to provide the desired product which was used directly in the next reaction.

[0152] t-Butyl 4-(indolin-1-yl)piperidine-1-carboxylate (I-1): See General Procedure A: indoline (10.0 g, 83.9 mmol, 1.00 equiv), N-Boc piperidone (17.6 g, 88.1 mg, 1.05 equiv), AcOH (4.80 mL, 83.9 mmol, 1.00 equiv), STAB (26.7 g, 12.6 mmol, 1.50). No MgSO was used in the reaction. The crude oil was purified by flash chromatography using 10:90 EtOAc:hexanes to provide indoline I-1 (24.3 g, 96% yield). 1 H NMR (300MHz, CDCl3)δ 7.06(t, J=6.0Hz, 2H), 6.03(t, J=6.0Hz, 1H), 6.43(d, J=6.0Hz, 1H), 4.25(m, 2H), 3.52(m, 1H), 3.35(t, J=6.3Hz, 2H), 2.79(m, 2H), 1.80(d, J=9.3Hz, 2H), 1.60(m, 4H), 1.49(s, 9H);MS(APCI)m / z:303.06[M+H] + .

[0153] General Procedure B: Boc removal and reductive amination with 4-iPr cyclohexanone: Step 1. A solution of the N-Boc intermediate (1.00 equiv.) in CHCl (0.25–0.30 M) was cooled to 0°C, and then TFA (6–30 equiv.) was added over several minutes. After the addition was complete, the ice bath was removed, and the reaction was allowed to warm to room temperature and confirmed by TLC (EtOAc:hexanes). After 2 h, the reaction was complete. The reaction was concentrated in vacuo, followed by the addition of EtOAc, which was subsequently removed in vacuo. The oil residue was then dissolved in EtOAc and stirred with the addition of saturated NaHCO (aq.) until the aqueous layer remained basic. The layers were separated, and the aqueous layer was extracted with EtOAc (3–8 times) until UV activity in the aqueous layer was minimized. The EtOAc layers were combined, washed with brine, dried over MgSO, filtered, and concentrated in vacuo to provide the piperidine intermediate.

[0154] Step 2. The piperidine intermediate from the previous step (1.00 equiv.) and 4-iPr-cyclohexanone (1.00–1.50 equiv.) were dissolved in 1,2-DCE (0.070 M). Glacial AcOH (1.00–2.30 equiv.) was added to the reaction, and the reaction was stirred for 20 min. After 20 min, STAB (1.50–2.30 equiv.) was added in three portions. An Ar balloon was attached to the top of the reaction, and the reaction was monitored by TLC (MeOH:CHCl:NHOH (aq.)). After 2–3 days, the reaction was ≥95% complete; therefore, saturated NaHCO (aq.) was added until the aqueous layer remained basic. At this stage, the layers were separated, and the aqueous layer was extracted twice with CHCl. The organic layers were combined, washed twice with H2O, brine, dried over MgSO4, filtered, and concentrated in vacuo to provide a crude residue which was purified by flash chromatography using EtOAc:hexanes:NH4OH (aq.).

[0155] syn-1-(1-(4-isopropylcyclohexyl)piperidin-4-yl)indoline (I-2): See General Procedure B: Step 1. Indoline I-1 (24.4 g, 80.5 mmol, 1.00 eq), TFA (38.0 mL, 496 mmol, 6.20 eq), CHCl (300 mL, 0.27 M). The combined EtOAc layers were immediately dried over MgSO and were not washed with water or brine. A gray solid (13.6 g, 84% yield) was obtained. Step 2. See General Procedure B: NH piperidine from the previous step (13.6 g, 67.2 mmol, 1.00 equiv), iPr-cyclohexanone (9.40 g, 67.2 mmol, 1.00 equiv), AcOH (3.85 mL, 67.2 mmol, 1.00 equiv), STAB (21.3 g, 101 mmol, 1.50 equiv). Purification by flash chromatography using 10:90:1.5 EtOAc:hexanes:NHOH (aq.) provided intermediate I-2 as a pale gold oil (33% yield). f = 0.25 (20:80:3 drops of EtOAc:hexane:NH4OH(aq.), UV); 1H NMR (300MHz, CDCl3)δ 7.05(t, J=5.7Hz, 2H), 6.60(J=5.7Hz, 1H), 6.41(d, J=5.7Hz, 1H), 3.37(m, 3H), 3.10(d, J=8.7Hz, 2H), 2.94(t, J=6.3Hz, 2H), 2. 27(m, 1H), 2.14(t, J=8.7Hz, 2H), 1.54-1.82(m, 11H), 1.38(m, 2H), 1.13(m, 1H), 0.88(d, J=5.1Hz, 6H);MS(ESI)m / z:327.4[M+H] + .

[0156] syn-1-(1-(4-isopropylcyclohexyl)piperidin-4-yl)-1H-indole (61): Indoline I-2 (4.63 g, 14.2 mmol, 1.00 equiv.) was dissolved in 180 mL of CHCl. ​​To this solution was added 4 Å MS (56.8 g, 4 g / mmol of indoline), followed by MnO (12.3 g, 142 mmol, 10.0 equiv.) and an additional 20 mL of CHCl. ​​An argon balloon was placed over the reaction vessel, and the thick suspension was stirred and confirmed by TLC (20:80:3 drop EtOAc:hexane:NHOH (aq.)). After 16 h, the reaction was complete. The mixture was filtered through a large Celite pad, and the residual solid was washed five times with CHCl. ​​The filtrate was concentrated in vacuo to provide a crude oil. This material was dissolved in EtOAc, and 10% HCl (aq.) was added with vigorous stirring, resulting in the formation of a white precipitate. The white solid was filtered, washed three times with EtOAc, and then air-dried for 1 hour. The white solid was then suspended in EtOAc, and 70% NaHCO3 (aq.) was added, and the mixture was stirred until >90% of the solid was dissolved. The EtOAc layer was separated, washed with HO, brine, dried over MgSO4, filtered, and concentrated in vacuo to provide a viscous oil, which was purified by flash chromatography using 10:90:1.5 EtOAc:hexane:NH4OH (aq.) to provide indole 1 as an off-white solid (3.65 g, 79% yield). f = 0.25 (10:90:3 drops of EtOAc:hexane:NH4OH(aq.), UV); 1H NMR (300MHz, CDCl3)δ 7.64(d, J=6.0Hz, 1H), 7.39(d, J=6.0Hz, 1H), 7.26(m, 1H), 7.20(t, J=6.0Hz, 1H), 7.11(t, J=6.0Hz, 1H), 6.52(d, J=2.4Hz, 1H), 4.23(m, 1H), 3.20 (d. + .

[0157] syn-1-(1-(4-isopropylcyclohexyl)piperidin-4-yl)-1H-indole-3-carbaldehyde (I-3): To a stirred solution of 25.0 mL DMF at 0 °C was added POCl (3.66 mL, 40.0 mmol, 4.00 equiv.). The solution was stirred at 0 °C for 15 min. At this stage, indole I-3 (3.10 g, 10.0 mmol, 1.00 equiv.) was dissolved in 10 mL DMF, and dissolution was aided by heat. The warm solution of indole I-3 was then added to the reaction, which was rinsed with 5.00 mL DMF. The reaction was now a red solution, and the reaction was allowed to stir at 0 °C for 15–20 min. TLC (50:50:3 drops of EtOAc:hexane:NHOH (aq.)) indicated the reaction was complete. The reaction was poured into a saturated NaHCO3 (aq.) ice bath, followed by the addition of CHCl2. The mixture was stirred vigorously for 30 minutes, after which the layers were separated and the aqueous layer was extracted with CHCl2 (5-6 times) until UV activity was minimal. The organic layer was then washed three times with H2O, brine, dried over MgSO4, filtered, and concentrated in vacuo to provide a dark red oil, which was purified by flash chromatography using 50:50:1.5 EtOAc:hexanes:NH4OH (aq.) to provide aldehyde I-3 as a pale yellow solid (2.15 g, 74% yield). f = 0.20 (50:50:3 drops of EtOAc:hexane:NH4OH(aq.), UV); 1H NMR (300MHz, CDCl3)δ 10.0(s, 1H), 8.33(m, 1H), 7.89(s, 1H), 7.43(m, 1H), 7.33(m, 2H), 4.29(m, 1H), 3.28(d, J=7.8Hz, 2H), 2.40(m, 3H), 2.19(m, 3H), 1.55-1.78(m, 8H), 1.42(m, 2H), 1.17(m, 1H), 0.9(d, J=5.7Hz, 6H); MS(ESI)m / z:353.1[M+H] + .

[0158] syn-1-(1-(4-isopropylcyclohexyl)piperidin-4-yl)-1H-indole-3-carbaldehyde oxime (81): Aldehyde I-3 (2.15 g, 6.10 mmol, 1.00 equiv.), NHOH·HCl (551 mg, 7.93 mmol, 1.30 equiv.), and NaOAc·3HO (1.08 g, 7.93 mmol, 1.30 equiv.) were placed in a round-bottom flask. Absolute EtOH (20.5 mL) and 10 mL of HO were added, and the reaction was fitted with a condenser and topped with an argon balloon. The suspension was heated to reflux (oil bath ca. 110 °C) and checked by TLC (40:60:3 drop EtOAc:hexane:NHOH (aq.)). After 2 h, the reaction was complete. After the reaction was cooled to room temperature, a white precipitate formed. The mixture was diluted with EtOAc and saturated NaHCO3 (aq.) and stirred until the mixture became a biphasic solution. The layers were separated, and the organic layer was washed twice with HO, brine, dried over MgSO4, filtered, and concentrated in vacuo to provide oxime 2 as a white solid (1.74 g, 78% yield). The two isomers of the oxime were in a ratio of approximately 3:2. R f = 0.50 (top spot), 0.45 (bottom spot) (40:60:3 drops of EtOAc:hexane:NH4OH(aq.), UV); 1H NMR (300MHz, CDCl3, main isomer) δ 10.8(br, 1H), 8.47(s, 1H), 7.78(m, 2H), 7.41(d, J=6.0, 1H), 7.28(m, 1H), 7.23(m, 1H), 4.31(m, 1H), 3.30(d, J=8.7Hz, 2H), 2 .55(m, 1H), 2.46(t, J=7.8, 2H), 2.23(m, 3H), 1.86(m, 2H), 1.60-1.80(m, 6H), 1.43(m, 2H), 1.19(m, 1H), 0.91(d, J=5.1, 6H); 1 H NMR (300MHz, CDCl3, minor isomers) δ 8.30(s, 1H), 8.07(d, J=6.0Hz, 1H), 7.48(s, 1H), 7.40(d, J=6.0Hz, 1H), 7.28(t, J=5.4Hz, 1H), 7.20(t, J=5.4Hz, 1H), 4.23(m, 1H), 3.22( d, J=5.7Hz, 2H), 2.35(m, 3H), 2.13(m, 4H), 1.55-1.80(m, 7H), 1.43(m, 2H), 1.17(m, 1H), 0.91(d, J=5.1Hz, 6H);MS(ESI)m / z:368.5[M+H] + .

[0159] Example 2: Synthesis of benzyl ((1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methyl)carbamate (17) and (1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanamine (3) Scheme II illustrates this synthesis.

[0160] Scheme II [ka] Reagents and conditions for Scheme II: a) i. N-Boc piperidone, AcOH, STAB, MgSO4, DCE, room temperature (General Procedure A), ii. TFA, CHCl2, iii. 4-isopropyl-cyclohexanone, STAB, AcOH, DCE (General Procedure B, 2 steps); b) i. benzylprop-2-yn-1-ylcarbamate, cat. PdCl2(PPh3)2, catalytic copper(I) iodide (CuI), DMF:iso-Pr2NEt (3:1), ii. cat. Cu(OAc)2, PhMe, reflux (General Procedure C, 2 steps); and c) H2 balloon, cat. 10% Pd / C, NH3 / MeOH.

[0161] syn-N-(2-iodophenyl)-1-(4-isopropylcyclohexyl)piperidin-4-amine (II-1): i. See General Procedure A. 2-Iodoaniline (15.0 g, 63.3 mmol, 1.00 equiv.), N-Boc-piperidone (18.5 g, 95.0 mmol, 1.50 equiv.), glacial AcOH (8.40 mL, 146 mmol, 2.30 equiv.), STAB (30.9 g, 146 mmol, 2.30 equiv.), DCE (250 mL, 0.25 M). No MgSO4 was used in the reaction. The product was purified by flash chromatography using 5:95 EtOAc:hexanes to provide the desired bicyclic compound as a white solid (75% yield), which was used directly in the next reaction. R f = 0.15 (5:95 EtOAc:hexane, UV).

[0162] ii. See General Procedure B: Step 1. N-Boc piperidine (43.5 g, 0.108 mol, 1.00 equiv), TFA (200 mL, 2.61 mol, 24.0 equiv), CHCl (300 mL, 0.36 M). The NH piperidine intermediate was obtained as a light tan solid (42.0 g, 128% yield with NaTFA) and used directly in the next step.

[0163] See General Procedure B: Step 2. NH-Piperidine (0.108 mol, 1.00 equiv.), 4-iPr-cyclohexanone (22.7 g, 0.162 mol, 1.50 equiv.), glacial AcOH (14.2 mL, 0.248 mol, 2.30 equiv.), STAB (52.6 g, 0.248 mol, 2.30 equiv.), DCE (1.54 L, 0.070 M). Compound II-1 was purified by flash chromatography using 6:94:1.5 → 9:91:1.5 EtOAc:hexane:NHOH (aq.) to afford a golden oil. (The syn diastereomer has a higher R relative to the anti diastereomer.) F The purified oil was dissolved in EtOAc and transferred to an Erlenmeyer flask, followed by the addition of 10% HCl (aq.). After the addition of 10% HCl (aq.), a white precipitate formed, and the suspension was stirred for 10 minutes. The white precipitate was then filtered, washed twice with EtOAc, and air-dried for 1 hour. The white precipitate was then suspended in EtOAc in an Erlenmeyer flask, and saturated NaHCO3 (aq.) was added until basic, followed by stirring overnight. At this stage, the mixture was now a clear, biphasic solution. The layers were separated, and the EtOAc layer was washed with brine, dried over MgSO4, filtered, and concentrated under vacuum to provide iodoaniline II-1 as a pale gold oil (24.0 g, 39% yield for three steps). R f = 0.30 (10:90:3 drops of EtOAc:hexane:NH4OH(aq.), UV); 1 H NMR(CDCl3, 300MHz)δ 7.65(dd, J=5.7, 0.9, 1H), 7.184(t, J=6.0, 1H), 6.58(d, J=6.0, 1H), 6.41(dt, J=5.7, 0.9, 1H), 4.12(d, J=5.7Hz, 1H), 3.36(m, 1H), 2.93 (m, 2H), 2.25(m, 3H), 2.15(d, J=8.4Hz, 2H), 1.47-1.74(m, 8H), 1.38(m, 2H), 1.13(m, 1H), 0.89(d, J=4.8Hz, 6H);MS(ESI)m / z:427[M+H] + .

[0164] General Procedure C: Sonogashira Coupling and Cyclization: Step 1. Iodoaniline (1.00 equiv.) and terminal alkyne (3.00–5.00 equiv.) were dissolved in DMF and iPr2NEt (3:1, 0.40 M). PdCl2(PPh3)2 (0.0400 equiv.) and CuI (0.100 equiv.) were added simultaneously to the reaction mixture. An argon balloon with a three-way adapter was placed on top of the reaction vessel, and the vessel was purged and then backfilled with argon (repeated three times in total). The reaction was covered with aluminum foil and left stirring overnight at ambient temperature. The reaction was monitored by TLC (EtOAc:Hexane:NH4OH (aq.)). After completion, the reaction was diluted with EtOAc and HO and stirred for 10 min. The two phases were separated, and the organic layer was washed twice with HO and brine, dried over MgSO4, filtered, and concentrated in vacuo. The resulting crude material was purified by flash chromatography and then used directly in the next reaction without further treatment.

[0165] Step 2. The internal alkyne from Step 1 (1.00 equiv.) was placed in a round-bottom flask. Cu(OAc)2 (0.200-0.400 equiv.) was added, followed by PhMe (0.25 M). The reaction was fitted with a reflux condenser, and then an argon balloon was attached to the top of the condenser. The reaction was then heated to reflux and checked by TLC (30:70:3 drops of EtOAc:hexane:NH4OH (aq.)). After 1-2 h, TLC indicated the reaction was complete. The reaction was allowed to cool to room temperature, EtOAc and H2O were added, and the mixture was stirred for 30 min. The mixture was filtered through a Celite pad, and the Celite pad was washed 3-4 times with EtOAc. The layers were separated, and the organic layer was washed once with H2O. The aqueous layers were combined and extracted once with EtOAc. The organic layers were combined, washed with brine, dried over MgSO4, filtered, and concentrated in vacuo to provide a crude solid. This solid was adsorbed onto silica gel, loaded onto a column, and purified by flash chromatography to provide the pure indole intermediate.

[0166] syn-Benzyl ((1-(1-(4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methyl)carbamate (17): i. See General Procedure C: Step 1. Iodoaniline II-1 (5.60 g, 13.1 mmol, 1.00 equiv), N-benzylprop-2-yn-1-ylcarbamate (8.69 g, 45.9 mmol, 3.50 equiv), DMF (25.0 mL) and iPrNEt (8.25 mL), PdCl(PPh) (368 mg, 0.524 mmol, 0.0400 equiv), and CuI (250 mg, 1.31 mmol, 0.100 equiv). The crude product was purified by flash chromatography using 20:80:1.5 to 5:75:1.5 EtOAc:hexanes:NH4OH (aq.) to provide the desired internal alkyne as a pale yellow solid (6.26 g, 98% yield), which was used directly in the next reaction. f = 0.25 (25:75:3 drops of EtOAc:hexane:NH4OH (aq.), UV).

[0167] See General Procedure C: Step 2. Internal alkyne (6.26 g, 12.8 mmol, 1.00 equiv), Cu(OAc) (700 mg, 3.85 mmol, 0.300 equiv), and PhMe (51.0 mL, 0.25 M). The crude solid was purified by flash chromatography using 15:85:1.5 to 20:80:1.5 to 30:70:1.5 EtOAc:hexanes:NHOH (aq.) to provide a pale yellow solid. This solid was triturated with a minimal amount of 1:1 EtOAc:hexanes to provide indole 3 as a white solid (64% yield over two steps). f = 0.30 (25:75:3 drops of EtOAc:hexane:NH4OH(aq.), UV); 1H NMR(CDCl3, 300MHz)δ 7.65(d, J=8.1Hz, 1H), 7.55(d, J=7.8Hz, 1H), 7.32(m, 5H), 7.16(t, J=8.1Hz, 1H), 7.17( t, J=7.8Hz, 1H), 6.38(s, 1H), 5.17(s, 2H), 4.90(br, 1H), 4.59(d, J=5.7Hz, 2H), 4.15(m, 1H), 3.10(d, J=10.2Hz, 2H), 2.57(dq, J=12.6, 3.3Hz, 2H), 2.31(m, 1H), 2.10(t, J=12.6H) z, 2H), 1.35-1.80(m, 11H), 1.17(m, 1H), 0.93(d, J=6.9Hz, 6H);MS(ESI)m / z:488.4[M+H] + .

[0168] syn-(1-(1-(4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanamine (3): Indole 17 (2.83 g, 5.80 mmol, 1.00 equiv) and 10% Pd / C (425 mg, 15% w / w) were suspended in a 7N NH in MeOH mixture. The reaction vessel was equipped with a H balloon, purged of air, refilled with H, and then repeated (total of 3 times). Over the next 2-3 h, indole 17 slowly dissolved and the reaction was monitored by TLC (100:3 dropwise EtOAc:NHOH (aq.). After a total of 4 h, the reaction was complete. The reaction mixture was filtered over a Celite pad and washed thoroughly with MeOH. The filtrate was concentrated in vacuo, and the crude material was purified by flash chromatography using 0:100:1.5 to 2:98:1.5 MeOH:EtOAc:NHOH (aq.) to provide diamine 3 as a white solid (2.00 g, 98% yield). f = 0.35 (5:95:3 drops of MeOH: EtOAc: NH4OH (aq.), UV); 1H NMR (300MHz, CDCl3)δ 7.64(d, J=6.3Hz, 1H), 7.56(d, J=5.4Hz, 1H), 7.14(dt, J=5.4, 0.9Hz, 1H), 7.06(dt, J=5 .4, 0.9Hz, 1H), 6.38(s, 1H), 4.25(m, 1H), 4.04(s, 2H), 3.20(d, J=9.0Hz, 2H), 2.61(dq, J =7.2, 1.8Hz, 2H), 2.36(m, 1H), 2.24, (t, J=8.4Hz, 2H), 1.87(dd, J=9.3, 1.5Hz, 2H), 1.50 -1.80(m, 8H), 1.42(m, 2H), 1.16(m, 1H), 0.92(d, J=4.8Hz, 6H);MS(ESI)m / z:354.5[M+H] + .

[0169] Example 3 Synthesis of (1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (30) and (E)-1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indole-2-carbaldehyde oxime (1) Scheme III illustrates this synthesis.

[0170] Scheme III [ka] Reagents and conditions for Scheme III: a) i. terminal alkyne, cat. PdCl2(PPh3)2, cat. CuI, DMF:iPr2NEt (3:1), ii. cat. Cu(OAc)2, PhMe, reflux (General Procedure C, 2 steps); and b) i. MnO2, CH2Cl2, ii. NH2OH·HCl, NaOAc·3H2O, EtOH:H2O (2:1), 110 °C.

[0171] syn-(1-(1-(-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (30): See General Procedure C: Step 1. Iodoaniline II-1 (3.97 g, 9.30 mmol, 1.00 equiv), propargyl alcohol (2.61 g, 46.5 mmol, 5.00 equiv), DMF (17.2 mL) and iPrNEt (5.8 mL), PdCl(PPh) (261 mg, 0.372 mmol, 0.0400 equiv), and CuI (177 mg, 0.930 mmol, 0.100 equiv). The crude product was purified by flash chromatography using 40:60:1.5 to 50:50:1.5 EtOAc:hexanes:NHOH (aq.) to provide the desired internal alkyne as a dark red paste (2.86 g, 87% yield), which was used directly in the next reaction.

[0172] See General Procedure C: Step 2. Internal alkyne (2.86 g, 8.07 mmol, 1.00 equiv), Cu(OAc) (440 mg, 2.42 mmol, 0.300 equiv), and PhMe (32.3 mL, 0.25 M). This material (adsorbed on silica gel) was loaded onto a column and purified by flash chromatography using 25:75:1.5 to 35:65:1.5 EtOAc:hexanes:NHOH (aq.) to provide a pale yellow solid. This solid was triturated with a minimal amount of 1:1 EtOAc:hexanes to provide indole 30 as a white solid (1.82 g, 56% yield over two steps). f = 0.25 (25:75:3 drops of EtOAc:hexane:NH4OH(aq.), UV); 1H NMR (400MHz, CDCl3)δ 7.69(d, J=8.0Hz, 1H), 7.58(d, J=8.0Hz, 1H), 7.18(t, J=7.6Hz, 1H), 7.08(t, J=7.6Hz, 1H ), 6.44(s, 1H), 4.81(d, J=4.8Hz, 2H), 4.37(m, 1H), 3.19(d, J=11.6Hz, 2H), 2.61(dq, J=12 .4, 3.2Hz, 2H), 2.37(m, 1H), 2.26(t, J=11.6Hz, 2H), 1.89(d, J=12.0Hz, 2H), 1.70(m, 5H) , 1.55(m, 2H), 1.40(m, 2H), 1.16(m, 1H), 0.92(d, J=6.8Hz, 6H); MS(ESI)m / z:355.27[M+H] + .

[0173] syn-1-(1-(4-isopropylcyclohexyl)piperidin-4-yl)-1H-indole-2-carbaldehyde oxime (1): i. To a solution of indole 30 (1.30 g, 3.67 mmol, 1.00 equiv.) in 36.7 mL of CHCl, MnO (3.83 g, 44.0 mmol, 12.0 equiv.) was added at room temperature, and the reaction was left stirring overnight. At this stage, TLC (30:70:1.5 EtOAc:hexanes:NHOH (aq.)) indicated the reaction was complete. The reaction was filtered over a Celite pad, washed three times with CHCl, and the filtrate was concentrated in vacuo to provide the aldehyde as a paste (1.27 g, 98%). This compound was used directly in the next step.

[0174] ii. The latter aldehyde (1.26 g, 3.57 mmol, 1.00 equiv.), NHOH·HCl (372 mg, 5.36 mmol, 1.50 equiv.), and NaOAc·3HO (730 mg, 5.36 mmol, 1.50 equiv.) were all placed in a round-bottom flask. EtOH (12.0 mL) and HO (6.00 mL) were then added, and the reaction was fitted with a reflux condenser topped with an argon balloon. The reaction (white suspension) was then heated to 110 °C. At approximately 50 °C, the reaction became a pale yellow solution, and at approximately 70–80 °C, a white precipitate began to form. At 110 °C, the reaction was now a thick white slurry, and after 10 min, TLC (20:80:3 drops of EtOAc:hexane:NHOH (aq.)) indicated the reaction was complete. The reaction was allowed to cool to room temperature, and CHCl and saturated NaHCO (aq.) were added, and the mixture was stirred for 20 minutes to provide a clear, biphasic mixture. The layers were separated, and the aqueous layer was extracted once with CHCl. ​​The organic layers were combined, washed twice with H0, brine, dried over MgSO, filtered, and concentrated in vacuo to provide a white foam. To this foam was added 2 mL of EtOAc, followed by 10 mL of MeOH, and the suspension was stirred for 10 minutes. The solid was then filtered, washed three times with cold MeOH, and dried in vacuo to provide oxime 1 as a white solid (1.10 g, 84% yield). f = 0.25 (20:80:3 drops of EtOAc:hexane:NH4OH(aq.), UV); 1 H NMR (CDCl3, 300 MHz) δ 10.7(br, 1H), 8.70(s, 1H), 7.59(m, 2H), 7.18(t, J=5.7Hz, 1H), 7.07(t, J =5.7Hz, 1H), 6.83(s, 1H), 4.89(m, 1H), 3.24(d, J=8.4Hz, 2H), 2.65(dq, J= 9.6, 2.1Hz, 2H), 2.45(m, 1H), 2.31(t, J=8.7Hz, 2H), 1.56-1.93(m, 9H), 1 .43(m, 2H), 1.19(m, 1H), 0.94(d, J=4.8Hz, 6H);MS(ESI)m / z:368.32[M+H] + .

[0175] Example 4 Synthesis of 2-(1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)ethan-1-ol (32) and 2-(1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)ethylsulfamate (11) Scheme IV illustrates this synthesis.

[0176] Scheme IV [ka] Reagents and conditions for Scheme IV: a) i. Terminal alkyne, cat. PdCl2(PPh3)2, cat. CuI, DMF:iso-Pr2NEt (3:1), ii. cat. Cu(OAc)2, PhMe, reflux (General Procedure C, 2 steps), iii. TBAF, THF, and b) ClSO2NH2, CH2Cl2.

[0177] syn-2-(1-(1-(4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)ethan-1-ol (32): i. See General Procedure C: Step 1. Iodoaniline II-1 (1.60 g, 3.75 mmol, 1.00 equiv), (but-3-yn-1-yloxy)(tert-butyl)dimethylsilane (2.41 g, 13.1 mmol, 3.50 equiv), DMF (11.3 mL) and iPrNEt (3.80 mL), and PdCl(PPh) (105 mg, 0.150 mmol, 0.0400 equiv) and CuI (71.4 mg, 0.375 mmol, 0.100 equiv). The crude oil was purified by flash chromatography using 7:93:1.5 to 10:90:1.5 EtOAc:hexanes:NHOH (aq.) to provide the desired internal alkyne as a brown oil (1.60 g, 88% yield), which was used directly in the next reaction.

[0178] See General Procedure C: Step 2. Internal alkyne (1.60 g, 3.31 mmol, 1.00 equiv), Cu(OAc) (601 mg, 3.31 mmol, 1.00 equiv), and PhMe (13.3 mL, 0.25 M). Reaction time was 4 h. The crude material was purified by flash chromatography using a 2:98:1.5 to 6:94.15 mixture to provide the desired indole as a pale yellow oil (1.00 g, 63% yield), which was used directly in the next reaction.

[0179] ii. To a solution of the previously synthesized indole (1.10 g, 2.28 mmol, 1.00 equiv.) in 15.0 mL of THF, TBAF (1.0 M, 4.55 mL, 2.00 equiv.) was added at room temperature, stirred, and monitored by TLC (20:80:3 dropwise EtOAc:hexane:NH4OH (aq.)). Upon reaction completion (approximately 2 h), the reaction was concentrated in vacuo and the crude material was flushed using 25:75:1.5 to 50:50:1.5 EtOAc:hexane:NH4OH (aq.) to provide alcohol 32 as a white solid (792 mg, 94% yield). f = 0.25 (30:70:3 drops of EtOAc:hexane:NH4OH(aq.), UV); 1 H NMR(CDCl3, 300MHz)δ 7.65(d, J=9.0Hz, 1H), 7.55(d, J=9.0Hz, 1H), 7.13(t, J=5.4Hz, 1H), 7.07(t, J=5.4H z, 1H), 6.33(s, 1H), 4.14(m, 1H), 3.94(t, J=4.8Hz, 2H), 3.20(d, J=8.7Hz, 2H), 3.09( t, J=4.8Hz, 2H), 2.64(q, J=7.5Hz, 2H), 2.36(m, 1H), 2.22(t, J=8.7Hz, 2H), 1.51-1.8 7(m, 9H), 1.42(m, 2H), 1.27(m, 1H), 0.92(d, J=4.8Hz, 6H);MS(ESI)m / z:369.27[M+H] + .

[0180] syn-2-(1-(1-(4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)ethyl sulfamate (11): To a solution of alcohol 32 (200 mg, 0.543 mmol, 1.00 equiv) and iPrNEt (0.946 mL, 5.43 mmol, 10.0 equiv) in 5.00 mL of CHCl was added dropwise a solution (approximately 0.50 M in CHCl) of sulfamoyl chloride (7.00 mL, 3.26 mmol, 6.00 equiv) at 0 °C. The ice bath was removed and the reaction was stirred for 1 h. At this point, TLC (40:60:3 drops of EtOAc:hexanes:NH4OH (aq.) indicated the reaction was complete. The reaction was diluted with EtOAc, and then 10% NaHCO3 (aq.) was added. A white precipitate formed which was filtered and washed with EtOAc. The filtrate layers were separated, and the EtOAc layer was washed twice with HO, brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude material was flashed in 40:60:1.5 EtOAc:hexanes:NH4OH (aq.) to provide sulfamate 11 as a white solid (35 mg, 14% yield). R f = 0.25 (40:60:3 drops of EtOAc:hexane:NH4OH(aq.), UV); 1 H NMR (300MHz, CDCl3)δ 7.64(d, J=6.3Hz, 1H), 7.54(d, J=5.7Hz, 1H), 7.15(t, J=5.7Hz, 1H), 7.07(t, J=5.7Hz, 1H), 6. 34(s, 1H), 4.50(t, J=5.1Hz, 2H), 4.13(m, 1H), 3.28(t, J=5.1Hz, 2H), 3.22(d, J=8.4Hz, 2H), 2. 64(m, 2H), 2.40(m, 1H), 2.27(t, J=8.4Hz, 2H), 1.84(d, J=8.4Hz, 2H), 1.76(m, 2H), 1.55-1.70( m, 3H), 1.41(m, 2H), 1.26(m, 2H), 1.17(m, 1H), 0.92(d, J=5.1Hz, 6H);MS(ESI)m / z:448.3[M+H] + .

[0181] Example 5: Synthesis of (5-fluoro-1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (29) Scheme V illustrates this synthesis.

[0182] Scheme V [ka] Reagents and conditions for Scheme V: a) i. N-Boc piperidone, AcOH, STAB, MgSO4, DCE, room temperature (General Procedure A), ii. TFA, CHCl, iii. 4-iso-Pr-cyclohexanone, STAB, AcOH, DCE (General Procedure B, 2 steps); and b) i. terminal alkyne, cat. PdCl(PPh3)2, cat. CuI, DMF:iso-PrNEt (3:1), ii. cat. Cu(OAc)2, PhMe, reflux (General Procedure C, 2 steps).

[0183] syn-N-(4-fluoro-2-iodophenyl)-1-(4-isopropylcyclohexyl)piperidin-4-amine (V-1): i. See General Procedure A. 4-Fluoro-2-iodoaniline (3.80 g, 16.0 mmol, 1.00 equiv), N-Boc piperidone (4.69 g, 24.0 mmol, 1.50 equiv), MgSO (3.80 g, 100 wt%), glacial AcOH (2.11 mL, 36.8 mmol, 2.30 equiv), STAB (7.80 g, 36.8 mmol, 2.30 equiv), and DCE (80.0 mL, 0.20 M). The crude material was purified by flash chromatography using 12:88 EtOAc:hexanes to provide the desired bicyclic intermediate as a white solid (6.70 g, 99% yield), which was used directly in the next reaction.

[0184] ii. See General Procedure B: Step 1. N-boc piperidine intermediate (5.00 g, 11.9 mmol, 1.00 equiv), TFA (27.3 mL, 357 mmol, 30.0 equiv), CHCl (60.0 mL, 0.20 M). Workup of the reaction described above gave an off-white solid (4.94 g, 130% with NaTFA) which was used directly in the next reaction.

[0185] See General Procedure B: Step 2. NH piperidine intermediate (11.9 mmol, 1.00 equiv), 4-iPr-cyclohexanone (2.51 g, 17.9 mmol, 1.50 equiv), glacial AcOH (1.57 mL, 27.4 mmol, 2.30 equiv), MgSO (3.81 g, 100 wt%), STAB (5.81 g, 27.4 mmol, 2.30 equiv), and DCE (150 mL, 0.080 M). The crude material was purified by flash chromatography using 10:90:1.5 EtOAc:hexanes:NHOH (aq.) to provide intermediate V-1 as a dark orange-brown oil (55% yield over three steps). f = 0.25 (20:80:3 drops of EtOAc:hexane:NH4OH(aq.), UV); 1 H NMR(CDCl3, 300MHz)δ 7.41(dd, J=6.0, 2.1Hz, 1H), 6.95(dt, J=6.0, 2.1Hz, 1H), 6.51(dd, J=6.9, 3.6Hz, 1H), 3.91(d, J=6.0Hz, 1H), 3.28(m, 1H), 2.92 (m, 2H), 2.24(m, 3H), 2.04(m, 2H), 1.47-1.73(m, 8H), 1.38(m, 2H), 1.13(m, 1H), 0.88(d, J=5.1Hz, 6H);MS(ESI)m / z:445.1[M+H] + .

[0186] syn-(5-fluoro-1-(1-(4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (29): i. See General Procedure C: Step 1. Intermediate V-1 (600 mg, 1.35 mmol, 1.00 equiv), propargyl alcohol (378 mg, 6.75 mmol, 5.00 equiv), DMF (3.12 mL) and iPrNEt (1.13 mL), and PdCl(PPh) (38.0 mg, 0.0540 mmol, 0.0400 equiv) and CuI (25.7 mg, 0.135 mmol, 0.100 equiv). The crude material was purified by flash chromatography using 40:60:1.5 EtOAc:hexanes:NH4OH (aq.) to provide the desired internal alkyne as a brown-red oil (440 mg, 87%), which was used directly in the next reaction.

[0187] See General Procedure C: Step 2. Internal alkyne (440 mg, 1.18 mmol, 1.00 equiv), Cu(OAc) (64.4 mg, 0.354 mmol, 0.300 equiv), and PhMe (4.75 mL, 0.21 M). The crude material was purified by flash chromatography using 25:75:1.5 EtOAc:hexanes:NHOH (aq.) to provide a pale yellow solid. This solid was triturated with EtOAc to provide indole 29 as a white solid (143 mg, 29% yield over two steps). f = 0.20 (25:75:3 drops EtOAc:hexane:NH4OH(aq.), UV); 1H NMR (300MHz, CDCl3)δ 7.58(dd, J=9.0, 4.2Hz, 1H), 7.20(dd, J=9.3, 2.7Hz, 1H), 6.92(dt, J=9.3, 2.7Hz, 1H), 6.38(s, 1H), 4.78(s, 2H), 4.35(m, 1H), 3.19(d, J=11.7Hz, 2H), 2.55(dq, J=12.6, 3.6H z, 2H), 2.35 (m, 1H), 2.26 (dt, J=11.7, 1.8Hz, 2H), 1.88 (dd, J=12.0, 2.4Hz, 2H), 1.48- 1.79(m, 9H), 1.40(m, 2H), 1.15(m, 1H), 0.91(d, J=6.6Hz, 6H);MS(ESI)m / z:373.4[M+H] + .

[0188] Example 6: Synthesis of (1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indole-2,3-diyl)dimethanol (51) Scheme VI illustrates this synthesis.

[0189] Scheme VI [ka] Reagents and conditions for Scheme VI: a) (t-BuCO)2O, cat. DMAP, (isopropyl)2NEt, CH2Cl2; and b) i. POCl3, DMF, ii. NaBH4, EtOH, iii. NaOH, cat. Bu4NI, THF.

[0190] syn-(1-(1-(-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methyl pivalate (35): To a solution of alcohol 30 (7.29 g, 20.6 mmol, 1.00 equiv.) in CHCl (138 mL, 0.15 M) was added DMAP (503 mg, 4.12 mmol, 0.200 equiv.) and iPrNEt (18.4 mL, 103 mmol, 5.00 equiv.) at room temperature. Subsequently, (tBuCO)O (6.70 mL, 33.0, 1.60 equiv.) was added, and the reaction was left stirring overnight. TLC (30:70:3 drop EtOAc:hexane:NHOH (aq.)) indicated the reaction was complete. The reaction was concentrated in vacuo, and the crude oil was purified by flash chromatography using 5:95:1.5 EtOAc:hexane:NHOH (aq.) to provide 35 as a white solid (8.59 g, 95%). f = 0.70 (30:70: 3 drops of EtOAc:hexane:NH4OH(aq.), UV); 1 H NMR (400MHz, CDCl3)δ 7.73(d, J=8.4Hz, 1H), 7.60(d, J=8.0Hz, 1H), 7.20(t, J=7.2Hz, 1H), 7.09(t, J=7.2Hz, 1H) , 6.56(s, 1H), 5.25(s, 2H), 4.17(m, 1H), 3.31(d, J=12.0Hz, 2H), 2.78(q, J=12.0Hz, 2H), 2. 55(q, J=6.4Hz, 1H), 2.32(t, J=11.6Hz, 2H), 1.90(d, J=12.4Hz, 2H), 1.80(m, 2H), 1.64(m, 5 H), 1.43(m, 2H), 1.22(s, 9H), 1.20(m, 1H), 0.92(d, J=6.4Hz, 6H);MS(ESI)m / z:439.3[M+H] + .

[0191] syn-(1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1H-indole-2,3-diyl)dimethanol (51): i. POCl (9.43 mL, 103 mmol, 5.00 equiv.) was added to DMF (83.0 mL) at 0 °C, and the mixture turned pale yellow. Indole 35 (9.00 g, 20.6 mmol, 1.00 equiv.) was dissolved separately in 20 mL of DMF with the aid of heat and then allowed to cool back to room temperature. After stirring the POCl solution at 0 °C for 15 min, the solution of indole 35 was added slowly, forming a red solution. After complete addition, the reaction was stirred at 0 °C for 40 min. TLC (20:80:3 drop EtOAc:hexane:NHOH (aq.)) indicated the reaction was complete. The reaction was poured into an ice:NaHCO (saturated aq.) slurry, and then EtOAc was added. The mixture was stirred vigorously until it warmed to room temperature, and NaHCO3 (sat. aq.) was added to ensure a basic pH. The layers were separated, and the aqueous layer was extracted once with EtOAc. The EtOAc layers were combined, washed three times with water, brine, dried over MgSO4, filtered, and concentrated in vacuo to provide the aldehyde as a pale yellow solid (9.55 g, 99%), which was used directly in the next step.

[0192] ii. The aldehyde (9.55 g, 20.5 mmol, 1.00 equiv.) was suspended in anhydrous EtOH (100 mL, 0.20 M) and NaBH4 (1.55 g, 41.0 mmol, 2.00 equiv.) was added in several portions at room temperature. Note: An additional 1.00 equiv. of NaBH4 and a small amount of CHCl2 may be necessary to help solubilize the reaction mixture. The reaction was monitored by TLC (40:60:3 drops of EtOAc:hexane:NH4OH (aq.)) and, upon completion, the reaction was concentrated in vacuo to approximately 50% volume. EtOAc, followed by 50% NaHCO3 (aq.), was added, and the mixture was stirred until effervescence ceased. The layers were separated and the EtOAc layer was washed twice with water, brine, dried over MgSO4, filtered and concentrated in vacuo to provide a foam (9.60 g, quantitative yield) which was taken directly into the next step.

[0193] iii. The alcohol (9.60 g, 20.5 mmol, 1.00 equiv) was dissolved in THF (130 mL, 0.16 M), followed by the addition of Bu₄NI (1.51 g, 4.10 mmol, 0.20 equiv). Ground NaOH powder (8.20 g, 205 mmol, 10.0 equiv) was added at room temperature, and the reaction was stirred for approximately 90 minutes, at which time a thick, fluffy white precipitate formed. TLC (60:40:3 drop EtOAc:hexane:NH₄OH (aq.)) indicated the reaction was complete. The reaction was diluted with EtOAc and water, and the layers were separated. The aqueous layer was extracted twice with EtOAc, then the EtOAc layers were combined, washed twice with water, brine, dried over MgSO₄, filtered, and concentrated in vacuo. The crude material was purified by flash chromatography using 60:40:1.5 to 80:20:1.5 to 90:10:1.5 EtOAc:hexanes:NHOH (aq.) to provide diol 51 as a white foam (4.70 g, 60%). f = 0.20 (80:20:3 drops of EtOAc:hexane:NH4OH(aq.), UV); 1 H NMR (400MHz, CDCl3)δ 7.67 (d. 12.0Hz, 2H), 2.37(m, 1H), 2.25(t, J=11.0Hz, 2H), 1.52-1.89(m, 9H), 1.43(m, 2H), 1.18(m, 1H), 0.92(d, J=6.4Hz, 6H); MS(ESI)m / z:385.4[M+H] + .

[0194] Example 7: Synthesis of (E,Z)-3-(hydroxyimino)-1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)indolin-2-one (228) Scheme VII illustrates this synthesis.

[0195] Scheme VII [ka] Reagents and conditions for Scheme VII: a) HCO2NH4, Pd / C, 10%, MeOH, 2 h, 45 °C; b) 4-isopropylcyclohexanone, HOAc, MgSO4, NaBH(OAc)3, DCE, 48 h, room temperature; c) ceric ammonium nitrate (CAN), MeCN / H2O, 2 h, room temperature; d) NH2OH·HCl, NaOAc, EtOH / H2O, 20 h, room temperature.

[0196] 1-(Piperidin-4-yl)-2,3-dihydro-1H-indol-2-one (VII-2): To an ice-cold solution of 1-(1-benzylpiperidin-4-yl)-2,3-dihydro-1H-indol-2-one VII-1 (prepared by a procedure adapted from Forbes (2001) Tetrahedron Letters 2:6943-6945) (25.7 g, 82.6 mmol, 1.00 equiv) in 600 mL of MeOH was added ammonium formate (46.9 g, 743 mmol, 9.00 equiv), followed by an ice-cold slurry of Pd / C 10% (5.14 g) in 226 mL of MeOH. The reaction was fitted with a reflux condenser and heated to 45° C. for 2.5 h. The solution was filtered through a Celite pad and concentrated. Trituration with CHCl / MeOH 90 / 10 (500 mL total) followed by flash chromatography using CHCl / MeOH / NHOH 100 / 0 / 0 to 79 / 20 / 1 as eluent provided 15.94 g of the title material in 89% yield, in agreement with that reported (WO 2002 / 085357, Sun et al.).

[0197] 1-(1-((1s,4s)-4-Isopropylcyclohexyl)piperidin-4-yl)indoline-2,3-dione (VII-4): To a stirred solution of 1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)indolin-2-one (VII-3) (prepared from intermediate VII-2 according to Zaveri et al (2004) Journal of Medicinal Chemistry 47:2973-2976) (3.43 g, 10.1 mmol, 1.00 equiv.) in 336 mL of MeCN, was added CAN (22.1 g, 40.3 mmol, 4.00 equiv.) in 17.0 mL of HO, and the reaction was stirred at room temperature for 1 h. The reaction was diluted with CHCl and saturated NaHCO(aq). The layers were separated, and the aqueous solution was extracted twice with CHCl. The combined organic layers were filtered through a Celite pad, washed with saturated NaCl(aq), dried over NaSO, filtered, and concentrated. The residue was purified by flash chromatography using CHCl / MeOH 99 / 1 to 90 / 10 to provide 2.73 g of the title material in 76% yield. 1 H NMR (300MHz, CDCl3) 7.62 (1H, d, J=5.1Hz), 7.56 (1H, t, J=6Hz), 7.20 (1H, d, J=6Hz), 7.10 (1H, t, J=5.7Hz), 4.19-4.22 (1H, m), 3.16 (2H, d, J=8.7H z), 2.30-2.40 (3H, m), 2.20 (2H, t, J=8.1Hz), 1.60-1.79 (7H, m), 1.49-1 .54(2H, m), 1.36-1.43(2H, m), 1.13-1.15(1H, m), 0.90(6H, d, J=5.1Hz). MS(ESI)m / z 355.27(M+H) + .

[0198] (E,Z)-3-(hydroxyimino)-1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)indolin-2-one (228). To a stirred solution of intermediate VII-4 (500 mg, 1.41 mmol, 1.00 equiv) in EtOH (17.6 mL) was added hydroxylamine HCl (147 mg, 2.12 mmol, 1.50 equiv), followed by NaOAc (231 mg, 2.82 mmol, 2.00 equiv). HO (2.78 mL) was added to solubilize the reaction, and the reaction was stirred at room temperature for 20 h. The reaction was diluted with CHCl and saturated NaHCO(aq). The layers were separated, and the aqueous solution was extracted twice with CHCl. ​​The combined organic layers were washed twice with HO, dried over NaSO, filtered, and concentrated. The reaction was repeated on a 1.12 g scale and the two crude residues were combined. The residue was purified by trituration with 1 / 1 EtOAc / hexanes to provide 1.54 g of the title material in 91% yield. 1 H NMR (300MHz, DMSO-d6), 13.4 (1H, s), 8.00 (1H, d, J=9Hz), 7.40 (1H, t, J=9Hz), 7.18 (1H, d, J=6Hz), 7.05 (1H, t, J=6Hz), 4.00-4.02 (1H, m ), 3.06(2H, d, J=9Hz), 2.24-2.36(3H, m), 2.08(2H, t, J=12Hz), 1.52-1.69(7H, m), 1.31-1.44(4H, m), 1.06(1H, s), 0.85(6H, d, J=6Hz). MS(ESI)m / z 370.3(M+H) + .C 22 H 31 Analysis calculated for N3O2·1.00HCl·0.4H2O·0.1CH2Cl2: C, 62.95; H, 7.89; N, 9.97; Found: C, 62.61; H, 7.54; N, 9.73.

[0199] Example 8: Synthesis of 2-(1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-2-oxoindolin-3-yl)-N-methoxyacetamide (247) Scheme VIII illustrates this synthesis.

[0200] Scheme VIII [ka] Reagents and conditions for Scheme VIII: a) tert-butyl glyoxalate / DMSO, K2CO3, THF, activated molecular sieves, 2 h, 80 °C; b) H2(g), Pd / C, THF, 2 h, room temperature; c) TFA, CH2Cl2, 1.5 h, room temperature; d) NHOCH3·HCl, T3P, diisopropylethylamine, THF, 17 h, room temperature.

[0201] tert-Butyl 2-(1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-2-oxoindolin-3-ylidene)acetate (VIII-1). To a stirred solution of intermediate VII-3 (4.96 g, 14.6 mmol, 1.00 equiv) in THF (146 mL), tert-butyl glyoxalate, 34% solution in DMSO (prepared according to Yao et al., Tetrahedron, 2007, 63:10657-10670) (15.2 g, 117 mmol, 8.00 equiv) was added, followed by KCO (4.03 g, 29.1 mmol, 2.00 equiv) and activated molecular sieves (50 g). The reaction was fitted with a reflux condenser and stirred at 80 °C for 2 h. The reaction was allowed to cool to room temperature, filtered, and then diluted with EtOAc, HO, and a minimal amount of NaCl(aq). The layers were separated, and the aqueous solution was extracted twice with EtOAc. The combined organic layers were washed twice with NaCl(aq), dried over NaSO, filtered, and concentrated. The reaction was repeated on a 12.7 g scale, and the two crude residues were combined. The residue was purified by flash chromatography using hexane / EtOAc / NHOH 85 / 15 / 0 to 35 / 64 / 1 to give 16.9 g of the title material in 72% yield. 1H NMR (400MHz, CDCl3) 8.53 (1H, d, J=8Hz), 7.31 (1H, td, J=8, 4Hz), 7.10 (1H, d, J=8Hz), 7.02 (1H, t, J=8Hz), 6.83 (1H, s), 4.21-4.26 (1H, m), 3.1 3(2H, d, J=6Hz), 2.29-2.45(3H, m), 2.18(2H, t, J=12Hz), 1.59-1.71(7 H, m), 1.56 (9H, s), 1.34-1.52 (4H, m), 1.13 (1H, s), 0.89 (6H, d, J=8Hz). MS(ESI)m / z 453.3(M+H) + .

[0202] tert-Butyl 2-(1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-2-oxoindolin-3-yl)acetate (VIII-2). To a stirred solution of intermediate VIII-1 (3.05 g, 6.74 mmol, 1.00 equiv) in THF (67.0 mL) was added Pd / C 10% (305 mg). The reaction was degassed and replaced with 1 atmosphere of H2 (g). The reaction was stirred at room temperature for 2 hours, filtered through a Celite pad, and concentrated. The reaction was repeated on 7.00 g and 6.80 g scales, and the three crude residues were combined. This residue was purified by flash chromatography using hexane / EtOAc / NH4OH 95 / 5 / 0 to 35 / 64 / 1 to provide 12.9 g of the title material in 76% yield. MS(ESI)m / z 455.4(M+H) + . 1 H NMR (400MHz, CDCl3) 7.26 (1H, d, J=8Hz), 7.22 (1H, d, J=8Hz), 7.16 (1H, d, J=8Hz) ), 7.00(1H, t, J=8Hz), 4.25-4.29(1H, m), 3.73-3.76(1H, m), 3.13(2H, d, J=12Hz ), 2.97(1H, dd, J=16, 8Hz), 2.65(1H, dd, J=16, 8Hz), 2.28-2.45(4H, m), 2.18(2H , t, J=12Hz), 1.48-1.72(10H, m), 1.39(9H, s), 1.12(1H, s), 0.89(6H, d, J=8Hz).

[0203] 2-(1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-2-oxoindolin-3-yl)acetic acid with 2,2,2-trifluoroacetic acid compound (VIII-3). To an ice-cold solution of intermediate VIII-2 (12.9 g, 28.4 mmol, 1.00 equiv) in CHCl (284 mL) was added TFA (284 mL) in portions. The reaction was warmed to room temperature and stirred for 1.5 h. The reaction was concentrated and azeotroped five times with toluene to dryness to provide 14.5 g of the title material as the TFA salt in >100% yield. MS (ESI) m / z 399.2 (M+H) + .

[0204] 2-(1-(1-((1s,4s)-4-isopropylcyclohexyl)piperidin-4-yl)-2-oxoindolin-3-yl)-N-methoxyacetamide (247). To a stirred solution of intermediate VIII-3, 78% free base equivalent (641 mg, 1.25 mmol, 1.00 equiv) in THF (15.7 mL), O-methylhydroxylamine HCl (943 mg, 11.29 mmol, 9.00 equiv) was added, followed by DiPEA (3.93 mL, 22.6 mmol, 18.0 equiv), and the reaction was stirred at room temperature for 5 minutes. Propylphosphonic anhydride solution (T3P®) (2.24 mL, 7.53 mmol, 6.00 equiv) was added, and the reaction was stirred at room temperature for 17 hours. The reaction was diluted with EtOAc and HO. The layers were separated, and the aqueous solution was extracted twice with EtOAc. The combined organic layers were filtered through a Celite pad, washed with saturated NaCl(aq), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography using [hexane / EtOAc] / iPrOH / NH4OH 100 / 0 / 0 to 94 / 5 / 1 to give 336 mg of the title material in 63% yield. 1H NMR (400MHz, CDCl3) 9.79 (1H, s), 7.30 (1H, d, J=8Hz), 7.26 (1H, d, J=16Hz), 7.1 7(1H, d, J=8Hz), 7.03-7.06(1H, m), 4.24(1H, s), 3.79(3H, brs), 3.14(2H, d, J= 12Hz), 2.63-2.70(2H, m), 2.30-2.43(3H, m), 2.18(2H, t, J=12Hz), 1.59-1.71( 8H, m), 1.48-1.53 ​​(2H, m), 1.35-1.41 (2H, m), 1.14 (1H, s), 0.89 (6H, d, J=8Hz). MS(ESI)m / z 428.44(M+H) + .C 25 H 37 Analysis of N3O3: Calculated for 1.00 HCl·l0.9 H2O: C, 62.52; H, 8.35; N, 8.75; Found: C, 62.39; H, 8.20; N, 8.66.

[0205] Example 9: 2-(1′-(cis-4-isopropylcyclohexyl)-3-oxo-1H-spiro[isoquinoline-4,4′-piperidine]-2(3H)-yl)acetonitrile (339); 2-(2-aminoethyl)-1′-(cis-4-isopropylcyclohexyl)-1,2-dihydro-3H-spiro[isoquinoline-4,4′-piperidine]-3-one (340); and N-(2-(1′-(cis-4-isopropylcyclohexyl)-3-oxo-1H-spiro[isoquinoline-4,4′-piperidine]-2(3H)-yl)ethyl)aminosulfonamide (344). Scheme IX illustrates this synthesis.

[0206] Scheme IX [ka] Reagents and conditions for Scheme IX: a) NaH, BrCHCN, THF, 14 h, room temperature; b) H, PtO hydrate, MeOH, concentrated HCl, 50° C., 3 h; c) chlorosulfonyl isocyanate, benzyl alcohol, CHCl, 5° C., then EtN, CHCl, amine, 14 h, room temperature; and d) H, 10% Pd / C, MeOH, NH, 4 h.

[0207] 2-(1'-(cis-4-isopropylcyclohexyl)-3-oxo-1H-spiro[isoquinoline-4,4'-piperidine]-2(3H)-yl)acetonitrile (339): To a solution of IX-1 (prepared as described by Mustazza, J. Med. Chem., 2008, 51:1058-1062) (1.65 g, 4.84 mmol) in 40 mL of THF under argon, 60% NaH in mineral oil (0.969 g, 24.2 mmol) was added in portions, and the mixture was stirred at room temperature for 0.5 h. The mixture was cooled in an ice bath, and a solution of bromoacetonitrile (1.74 g, 14.5 mmol) in 20 mL of THF was added dropwise over 0.25 h, allowed to warm to room temperature, and stirred for 14 h. The mixture was treated with saturated sodium bicarbonate, extracted with ethyl acetate, dried over magnesium sulfate, and evaporated to dryness. Purification by chromatography on silica gel eluting with methanol / ethyl acetate / hexane / ammonium hydroxide (2:49:49:0.1) gave 1.31 g of 339, 71% yield. A portion of the base was converted to the hydrochloride salt. 1 H NMR (300MHz, DMSO, d6)δ 10.2 (1H, m), 7.51 (1H, d, 6Hz), 7.41 (1H, t, J=6Hz), 7.35 (1H, t, 6Hz), 7.34 (1H, d, J=6Hz), 4.74 (2H, s), 4.56 (2H, s), 3.4 -3.5(4H, m), 3.2(1H, m), 2.18(2H, d, J=11Hz), 1.84(4H, m), 1.68(4H, m), 1.41(2H, m), 1.14(2H, m), 0.88(6H, d, J=5Hz). MS m / z 380(M+H) + .

[0208] 2-(2-Aminoethyl)-1'-(cis-4-isopropylcyclohexyl)-1,2-dihydro-3H-spiro[isoquinoline-4,4'-piperidin]-3-one (340). To a solution of 339 (1.37 g, 3.61 mmol) in 30 mL of methanol was added platinum oxide hydrate (178 mg) in 3.3 mL of concentrated hydrochloric acid and stirred at 50 °C for 3 h under a hydrogen atmosphere. The mixture was cooled to room temperature, filtered through Celite, and evaporated to dryness. The residue was purified by chromatography on silica gel eluting with methanol / dichloromethane / ammonium hydroxide (11:89:0.1), which gave 1.37 g of 340 in 90% yield. A portion of the base was converted to the hydrochloride salt. 1 H NMR (300MHz, DMSO, d6)δ 10.6(1H, m), 8.06(3H, m), 7.54(1H, d, J=6Hz), 7.38(1H, t, 6Hz), 7.32(1H, t, J=6Hz), 7.26(1H, d, J=6Hz), 4.68(2H, s), 3.68(2H, m), 3.45 (3H, m), 3.18 (2H, m), 3.03 (2H, m), 2.23 (2H, d, J=11Hz), 1.87 (4H, d, J=8Hz), 1.67 (3H, m), 1.41 (2H, m), 1.15 (1H, m), 0.88 (6H, d, J=5Hz). MS m / z 384(M+H) + .

[0209] Syn-phenyl(N-(2-(1'-(4-isopropylcyclohexyl)-3-oxo-1H-spiro[isoquinoline-4,4'-piperidine]-2(3H)-yl)ethyl)sulfamoyl)carbamate (IX-2): A solution of chlorosulfonyl isocyanate (0.76 g, 5.4 mmol) in 20 mL of dichloromethane was cooled in an ice bath under argon and treated with benzyl alcohol (0.58 g, 5.4 mmol). After stirring for 0.25 h, the mixture was added to a solution of IX-2 (1.29 g, 3.36 mmol) in 20 mL of dichloromethane containing triethylamine (0.68 g, 6.72 mmol), which was cooled in an ice bath under argon. The resulting mixture was stirred at 5°C for 1 h and then at room temperature for 14 h. The mixture was treated with saturated sodium bicarbonate, extracted with dichloromethane, dried over magnesium sulfate, and evaporated to dryness. Purification by chromatography on silica gel eluting with methanol / dichloromethane / ammonium hydroxide (3:97:0.1) provided 1.68 g of IX-2, 84% yield. 1 H NMR (300MHz, CDCl3)δ 7.28-7.38(6H, m), 7.11-7.25(3H, m), 6.94(1H, m), 5.27(1H, m), 5.07(2H, s), 4.31(1H, m), 3.57(3H, m), 3.2(4H, m) ), 3.0 (1H, m), 2.35 (1H, m), 2.04 (2H, m), 1.87 (5H, m), 1.58 (3H, m), 1.31 (2H, m), 1.18 (1H, m), 0.89 (6H, d, J=5Hz). MS m / z 597(M+H) + .

[0210] N-(2-(1'-(cis-4-isopropylcyclohexyl)-3-oxo-1H-spiro[isoquinoline-4,4'-piperidine]-2(3H)-yl)ethyl)aminosulfonamide (344): To a solution of IX-2 (1.51 g, 2.53 mmol) dissolved in 80 ml of methanol and 10 ml of 7 N ammonia in methanol, 10% Pd / C (150 mg) was added and stirred under hydrogen gas for 4 h. The mixture was filtered through Celite and evaporated to dryness. The residue was purified by chromatography eluting with methanol / ethyl acetate / hexane / ammonium hydroxide (14:43:43:0.1) to provide 0.625 g of 344, 40% yield. 1 H NMR (300MHz, CDCl3) 7.51 (1H, d, J=6Hz), 7.33 (1H, t, J=6Hz), 7.25 (1H, t, J=6Hz), 7.18 (1H, d, J=6Hz), 5.2 (1H, m), 4.57 (2H, s), 3.74 (2H, t, J=4Hz) ), 3.38 (2H, t, J=4Hz), 2.81 (3H, m), 2.33 (2H, m), 2.23 (2H, m), 2.04 (2H, m ), 1.71 (2H, m), 1.59 (6H, m), 1.36 (2H, m), 1.12 (1H, m), 0.87 (6H, d, 5Hz). MS m / z 463(M+H) + A portion of the base was converted to the hydrochloride. 24 H 38 N4O3S·HCl·H2O)C, H, N.

[0211] Example 10: Synthesis of 2-(1-(1-(cis-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-3-yl)ethan-1-amine (86) Scheme X illustrates this synthesis.

[0212] Scheme X [ka] Reagents and conditions for Scheme X: a) alkyne X-1, LiCl, K2CO3, cat. Pd(OAc)2, DMF, 100 °C; and b) AcCl, MeOH, room temperature.

[0213] tert-Butyl (2-(1-(1-(cis-4-isopropylcyclohexyl)piperidin-4-yl)-2-(triethylsilyl)-1H-indol-3-yl)ethyl)carbamate (X-2): Iodo-aniline II-2 (401 mg, 0.940 mmol, 1.00 equiv.), alkyne X-1 (320 mg, 1.13 mmol, 1.20 equiv.), and LiCl (39.8 mg, 0.940 mmol, 1.00 equiv.) were placed in a 100 mL round-bottom flask. DMF (13.4 mL, 0.070 M) was added, followed by KCO (390 mg, 2.82 mmol, 3.00 equiv.) and Pd(OAc) (21.1 mg, 0.0940 mmol, 0.100 equiv.). The reaction was fitted with a three-way adapter and an argon balloon, then purged with vacuum three times and backfilled with argon. The reaction was then heated in a 100 °C oil bath and monitored by TLC (20:80:3 drops of EtOAc:hexane:NH4OH (aq.)). After approximately 60 min, a black color formed in the reaction, and after approximately 80–90 min, TLC indicated the reaction was complete. The reaction was allowed to cool to room temperature, then diluted with EtOAc and HO and left stirring for 10 min. The reaction mixture was then filtered through a small Celite pad, the layers were separated, and the aqueous layer was extracted once with EtOAc. The EtOAc layers were combined, washed twice with HO, brine, dried over MgSO4, filtered, and concentrated in vacuo to provide the crude material, which was purified by flash chromatography using 8:92:1.5 EtOAc:hexane:NH4OH (aq.) to provide intermediate X-2 as a white foam (360 mg, 66%). R f = 0.30 (20:80:3 drops of EtOAc:hexane:NH4OH(aq.), UV, I2, pAA); 1H NMR (300MHz, CDCl3)δ 7.69(d, J=6.0Hz, 1H), 7.61(d, J=6.0Hz, 1H), 7.16(t, J=5.7Hz, 1H), 7.06(t, J=5. 7Hz, 1H), 4.56(m, 1H), 4.25(m, 1H), 3.40(q, J=4.8Hz, 2H), 3.21(d, J=8.7Hz, 2H), 3 .01(t, J=5.1Hz, 2H), 2.71(dq, J=8.7, 2.1Hz, 2H), 2.35(m, 1H), 2.15(t, J=8.7Hz, 2 H), 1.85-1.38(m, 21H), 1.16(m, 1H), 1.05-0.90(m, 20H);MS(ESI)m / z:467.6[M+H] + .

[0214] 2-(1-(1-(cis-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-3-yl)ethan-1-amine (86): AcCl (806 μL, 11.3 mmol, 6.00 equiv) was added to MeOH (19.0 mL, 0.10 M) at 0 °C, and the reaction was stirred for 5 min. Indole X-2 (1.10 g, 1.89 mmol, 1.00 equiv) was then added to the reaction. After stirring at 0 °C for 10 min, a white slurry formed. The ice bath was then removed, and the reaction was allowed to warm to room temperature and stirred for 4 h. After 4 h, TLC (10:90:3 drops of iPrOH:CHCl:NHOH (aq.)) indicated the reaction was complete. EtOAc (approximately 50 mL) was added to the stirred reaction, and after several minutes, a white precipitate formed. This white precipitate was filtered, washed three times with cold EtOAc, and dried under vacuum to provide the HCl salt of indole 86. 665 mg (80%) of the desired salt was obtained. R f = 0.10 (10:90:3 drops of iPrOH:CH2Cl2:NH4OH(aq.), UV, I2); 1H NMR (free base) (300MHz, CDCl3)δ 7.61(d, J=6.0Hz, 1H), 7.35(d, J=6.3Hz, 1H), 7.21(t, J=6.0Hz, 1H), 7.11(m, 2 H), 4.18(m, 1H), 3.19(d, J=8.7Hz, 2H), 3.03(t, J=4.8Hz, 2H), 2.93(t, J=4.8H z, 2H), 2.35(m, 1H), 2.26(dt, J=8.4, 1.8Hz, 2H), 2.07(m, 6H), 1.78-1.52(m, 7 H), 1.42(m, 2H), 1.15(m, 1H), 0.90(d, J=5.1Hz, 6H);MS(ESI)m / z:368.5[M+H] + .

[0215] Example 11: In vitro characterization of receptor binding affinities at nociceptin, μ, and κ opioid receptors All compounds were tested for their binding affinity at nociceptin (NOP), μ, and κ opioid receptors, as described below. The binding assays are rapid and simple, using Chinese hamster ovary cells transfected with human NOP or opioid receptors. The results of these assays are shown in Tables 4, 5, and 6, which provide a range of receptor binding affinities at nociceptin and opioid receptors for compounds of Formula (II), Formula (III), and Formula (IV), respectively.

[0216] Receptor binding affinities at NOP, μ, δ, and κ receptors were determined using radioligand binding assays, which used the following radioligands: [ 3 H]N / OFQ (in the case of NOP), [ 3 H]DAMGO (for μ-opioid receptors), and [ 3 H]U-696593 (for kappa opioid receptors). IC 50 The values ​​were determined by the curve fitting program Prism and the Ki values ​​were calculated using the formula Ki = IC 50 / (1+L / Kd), where K d teeth[ 3 H]- is the binding affinity of the radioligand, and L is the [ 3H]-radioligin concentration.

[0217] Cell culture: The entire receptor was present in CHO cells transfected with human receptor cDNA. Cells were cultured in 100 mm plastic culture dishes in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum in the presence of 0.4 mg / ml G418 and 0.1% penicillin / streptomycin. For binding assays, cells were detached from the plates upon reaching confluence.

[0218] Receptor binding: Binding to cell membranes was performed in a 96-well format as previously described by Zaveri, NT, et al., J. Med. Chem., 2004, 47:2973-2976; Adapa, ID, et al., Neuropeptides, 1997, 31(5):403-408; and Dooley, CT, et al., J. Pharmacol. Exp. Ther., 1977, 283(2):735-741. Cells were detached from plates using a rubber policeman and homogenized in Tris buffer using a Polytron homogenizer, then centrifuged once and washed again at 27,000 g for 15 minutes. The pellet was resuspended in 50 mM Tris, pH 7.5, and the suspension was used for binding to NOP, μ-, or κ-opioid receptors, respectively. 3 H]nociceptin, [ 3 H]DAMGO, or [ 3 The samples were incubated with [H]U69593. The total incubation volume was 1.0 ml, and the samples were incubated at 25°C for 60-120 minutes. The amount of protein in the binding reaction was approximately 15-30 μg. The reaction was terminated by filtration using a Tomtec 96 harvester (Orange, CT) with glass fiber filters. Bound radioactivity was counted in a Pharmacia Biotech β-plate liquid scintillation counter (Piscataway, NJ) and expressed as counts / minute. IC 50Values ​​were determined using at least six concentrations of the test compound and calculated using Graphpad / Prism (ISI, San Diego, CA). Ki values ​​were determined by the method of Cheng and Prusoff (Cheng, Y., et al., Biochem Pharmacol., 1973, 22(23):3099-3108).

[0219] With respect to the binding affinity of each compound in the table below, values ​​designated "A" represent a Ki of less than 15 nM; values ​​designated "B" represent a Ki of 15-150 nM; values ​​designated "C" represent a Ki of 150 nM-5000 nM, and values ​​designated "D" represent a Ki of greater than 5000 nM.

[0220] [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5]

[0221] [Table 5-1] [Table 5-2]

[0222] [Table 6-1] [Table 6-2]

[0223] The compounds disclosed herein have selectivity for NOP receptors ranging from 1-fold to >10,000-fold over mu and kappa opioid receptors.

[0224] While specific embodiments of the invention have been described herein for purposes of illustration, it will be appreciated from the foregoing that various modifications can be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

Claims

1. 1. A therapeutic agent for treating an opioid use disorder, comprising: Structural formula: 【Chemistry 1】 (In the formula, R １ and R ２ together with the carbon atom to which they are attached are aryl, substituted aryl, heteroaryl, or substituted heteroaryl; R ３ は、-CH ２ CO ２ CH ３ ,-CH ２ CO ２ CH(CH ３ ) ２ ,-CH ２ CO ２ H,-CH ２ C(O)NH ２ ,-(CH ２ ) ２ OCH ３ ,-(CH 2 ) 2 CO 2 C(CH 3 ) 3,-(CH 2 ) 2 OCOCH 3,-CH ２ CN, - (CH ２ ) ２ NH ２ ,-(CH ２ ) ２ NHC(NH)NH ２ ,-(CH ２ ) ２ NHC(O)CH(NH ２ (CH) ２ ) ３ NHC(NH)NH ２ ,-(CH ２ ) ２ NHSO ２ CH ３ ,-(CH ２ ) ２ NHSO ２ NH ２ ,-(CH ２ ) ２ NHC(O)NH ２ ,-(CH ２ ) ２ OH, -(CH ２ ) ２ NHC(S)NH ２ ,-(CH ２ ) ２ NHC(O)H,-(CH) ２ ) ２ OCH ２ Ph, -(CH) ２ ) ２ OC(O)NHCH ３ , 【Chemistry 2】 or 【Transformation 3】 or a substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, or substituted heteroarylalkyl; L is (C ３ ~C ８ ) cycloalkyl, (C ３ ~C ８ ) substituted cycloalkyl, (C ３ ~C ８ ) cycloheteroalkyl, (C ３ ~C ８ ) substituted cycloheteroalkyl, 【Chemistry 4】 or 【Transformation 5】 cyclohexyl substituted with or a salt, hydrate or solvate thereof, or a pharmaceutical composition thereof, The pharmaceutical composition comprises the compound of the structural formula and a pharmaceutically acceptable vehicle. Treatment drug.

2. L is (C ３ ~C ８ ) cycloalkyl, (C ３ ~C ８ ) substituted cycloalkyl, or (C ３ ~C ８ ) cycloheteroalkyl.

3. L is, 【Transformation 6】 (In the formula, n is 0, 1 or 2; K is -NR ３１ - or -O-, R ３１ is hydrogen) The therapeutic agent according to claim 2,

4. L is a substituted cyclohexyl group, or 【Transformation 7】 The therapeutic agent of claim 1, which is cyclohexyl substituted with:

5. L is, 【Transformation 8】 (In the formula, Z is alkyl, substituted alkyl, heteroalkyl, or substituted heteroalkyl; and U is hydrogen or alkyl. The therapeutic agent according to claim 4,

6. Z is 【Chemistry 9】 and The therapeutic agent of claim 5, wherein U is hydrogen.

7. L is 【Chemistry 10】 The therapeutic agent of claim 4, wherein the cyclohexyl is substituted with .

8. The compound has structural formula (IV): 【Chemistry 11】 wherein J is —CH— or —N—; R ４６ is alkyl, halo, -OR ４７ , -NHR ４８ , -CF ３ or -CN; p is an integer from 0 to 4; R ４７ represents hydrogen, alkyl, —(CO)NR ４９ R ５０ or -SO ２ NR ５１ R ５２ and R ４８ , R ４９ , R ５０ , R ５１ and R ５２ are independently hydrogen or alkyl. The therapeutic agent of claim 1, which is a compound of the formula:

9. The compound has the following structure: 【Chemistry 12】 The therapeutic agent of claim 1, having the formula:

10. The compound has the following structure: 【Chemistry 13】 The therapeutic agent of claim 1, having the formula:

11. The compound has the following structure: 【Chemistry 14】 The therapeutic agent of claim 1, having the formula:

12. A therapeutic agent for treating opioid-related disorders, comprising: The following structure: 【Chemistry 15】 or a salt, hydrate, or solvate thereof.

13. A therapeutic agent for treating opioid-related disorders, comprising: The following structure: 【Chemistry 16】 or a salt, hydrate, or solvate thereof, and a pharmaceutically acceptable vehicle.

14. A therapeutic agent for treating pain, The following structural formula: 【Chemistry 17】 (In the formula, R １ and R ２ together with the carbon atom to which they are attached are aryl, substituted aryl, heteroaryl, or substituted heteroaryl; R ３ は、-CH ２ CO ２ CH ３ ,-CH ２ CO ２ CH(CH ３ ) ２ ,-CH ２ CO ２ H,-CH ２ C(O)NH ２ ,-(CH ２ ) ２ OCH ３ ,-(CH 2 ) 2 CO 2 C(CH 3 ) 3,-(CH 2 ) 2 OCOCH 3,-CH ２ CN, - (CH ２ ) ２ NH ２ ,-(CH ２ ) ２ NHC(NH)NH ２ ,-(CH ２ ) ２ NHC(O)CH(NH ２ (CH) ２ ) ３ NHC(NH)NH ２ ,-(CH ２ ) ２ NHSO ２ CH ３ ,-(CH ２ ) ２ NHSO ２ NH ２ ,-(CH ２ ) ２ NHC(O)NH ２ ,-(CH ２ ) ２ OH, -(CH ２ ) ２ NHC(S)NH ２ ,-(CH ２ ) ２ NHC(O)H,-(CH) ２ ) ２ OCH ２ Ph, -(CH) ２ ) ２ OC(O)NHCH ３ , [Chemistry 18] or 【Chemistry 19】 or a substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, or substituted heteroarylalkyl; L is (C ３ ~C ８ ) cycloalkyl, (C ３ ~C ８ ) substituted cycloalkyl, (C ３ ~C ８ ) cycloheteroalkyl, (C ３ ~C ８ ) substituted cycloheteroalkyl, 【Chemistry 20】 or 【Chemistry 21】 cyclohexyl substituted with or a salt, hydrate or solvate thereof, or a pharmaceutical composition thereof, The pharmaceutical composition comprises the compound of the structural formula and a pharmaceutically acceptable vehicle. Treatment drug.

15. L is (C ３ ~C ８ ) cycloalkyl, (C ３ ~C ８ ) substituted cycloalkyl, or (C ３ ~C ８ ) cycloheteroalkyl.

16. L is, 【Chemistry 22】 (In the formula, n is 0, 1 or 2; K is -NR ３１ - or -O-, R ３１ is hydrogen) The therapeutic agent according to claim 15,

17. L is a substituted cyclohexyl group, or 【Chemistry 23】 The therapeutic agent of claim 14, wherein the cyclohexyl is substituted with .

18. L is, 【Chemistry 24】 (In the formula, Z is alkyl, substituted alkyl, heteroalkyl, or substituted heteroalkyl; and U is hydrogen or alkyl. The therapeutic agent according to claim 17,

19. Z is 【Chemistry 25】 and The therapeutic agent of claim 18, wherein U is hydrogen.

20. L is 【Chemistry 26】 The therapeutic agent of claim 17, wherein the cyclohexyl is substituted with .

21. The compound has structural formula (IV): 【Chemistry 27】 wherein J is —CH— or —N—; R ４６ is alkyl, halo, -OR ４７ , -NHR ４８ , -CF ３ or -CN; p is an integer from 0 to 4; R ４７ represents hydrogen, alkyl, —(CO)NR ４９ R ５０ or -SO ２ NR ５１ R ５２ and R ４８ , R ４９ , R ５０ , R ５１ and R ５２ are independently hydrogen or alkyl. The therapeutic agent of claim 14, which is a compound of the formula:

22. The compound has the following structure: 【Chemistry 28】 The therapeutic agent of claim 14, having the formula:

23. The compound has the following structure: 【Chemistry 29】 The therapeutic agent of claim 14, having the formula:

24. The compound has the following structure: 【Transformation 30】 The therapeutic agent of claim 14, having the formula:

25. A therapeutic agent used in the treatment of pain, having the following structure: 【Chemistry 31】 or a salt, hydrate, or solvate thereof.

26. 1. A method of treatment for use in treating pain in a non-human subject, comprising: The following structure: 【Chemistry 32】 or a salt, hydrate, or solvate thereof, and a pharmaceutically acceptable vehicle.

Images